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ABSTRACT
TOWARD AN IN VITRO BIOEQUIVALENCE TEST
by
Jie Sheng 
Chair: Gordon L. Amidon
Oral absorption of Biopharmaceutics Classification System (BCS) II drugs is 
limited by in vivo dissolution.  The current pharmacopeial in vitro dissolution
methodologies are designed for quality control, and do not reflect in vivo performance
criteria.  This project is an investigation into the key in vitro dissolution parameters: 
hydrodynamics, pH, surfactants/bile salts, and buffer species that are important to in vivo
dissolution.  Hydrodynamics, i.e., the convective contributor to dissolution, was 
examined through the stagnant diffusional layer thickness, happ, of fenofibrate in a USP 
dissolution apparatus II.  These results demonstrate that happ has different functional 
dependences depending on particle sizes and the paddle speed.  At 50 rpm, happ is linear
with square root of particle size ( ) within the range of 6.8-106 m.  In contrast,
at 100 rpm a transitional particle radius exists at 23.7 m, above which the relationship 
becomes constant.  Further, the effect of particle size and paddle speed on h
2 0.98R
app can be 
combined using dimensional analysis.
xi
In addition, key components of GI fluids such as pH, bile salts and buffer species 
were also investigated.  The effects of pH and surfactants on ketoprofen (a BCS II weak 
acid) were investigated.  The dramatic enhancement of in vitro solubility/dissolution
attributable to an increase of pH and presence of SLS mimics the in vivo
solubilization/dissolution behavior of ketoprofen, when the pH increases from 1 to 2 in 
the stomach to 5 to 6 in the duodenum.  Further, even at the same pH and buffer 
concentration, the importance of buffer species was demonstrated by a) 50-200% faster 
intrinsic dissolution rates of ketoprofen and indomethacin in USP SIF, FaSSIF 
phosphates than in various concentrations of bicarbonates more reflective of in vivo; and
b) the dependence of buffer differential on biopharmaceutical properties, e.g., drug pKa, 
solubility and diffusivity. Finally, simple phosphate buffers are recommended: at pH 6.5, 
ketoprofen and indomethacin require 13 -14 mM and 3-4 mM phosphate buffer to match
85% and 108% of the dissolution rates in 15 mM bicarbonate buffer, respectively.
In summary, this research demonstrates that to establish a meaningful in vitro





INFLUENCE OF FASTED STATE GASTROENTEROLOGICAL FACTORS ON 
IN VIVO DISSOLUTION OF POORLY SOLUBLE DRUGS  
 
Introduction 
Orally administered drug products are the most dominant dosage forms.  However, 
predicting oral drug absorption remains a challenge due to the variety of 
biopharmaceutical properties of the drug and drug products, as well as the complexity of 
gastrointestinal (GI) physiology.   
Gastrointestinal tract presents a complex environment for orally administered drugs.  
In healthy humans at fasted state, there are two important physiological factors impacting 
on drug dissolution and the subsequent absorption: 1). the hydrodynamics of GI tract; and 
2) the components of GI fluids.  The hydrodynamics of GI tract is intimately related to GI 
motility, which emcompasses gastric emptying, migrating motility complex (MMC), and 
the frequency and intensity of small intestine movement, while the critical GI fluid 
components are pH, bile salts and buffer species, volume, enzymes, osmolarity and 
calcium contents may be also important.  In addition, GI transit time and splanchnic 
blood flow may also play indirect roles in drug absorption.  All of these GI physiological 
factors are dynamically interacting with each other, which is further complicated by high 
variability within and between individuals.   
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Biopharmaceutical properties of the active pharmaceutical ingredient (API) are the 
inherent nature of a drug molecule, which determines the rate of drug dissolution and 
extent of drug absorption.  The biopharmaceutical classification system (BCS) proposed 
by Amidon et. al. has established the foundation for correlating the biopharmaceutical 
properties of an API with its in vivo performance.  The four BCS classes, based on drug 
solubility and permeability 1, are listed in Table 1.1.  BCS II drugs exhibit high 
permeability and low solubility, and their oral absorption is rate-limited by in vivo 
dissolution.  In light of the reality that more and more BCS II drugs are being discovered, 
investigating the correlation of in vitro dissolution of BCS II drugs with their in vivo 
performance, and gaining a mechanistic understanding of IVIVC warrants more research 
efforts.   
The objective of this project is to investigate the in vitro dissolution factors 
reflecting the in vivo dissolution GI physiological factors such as motility, pH, surfactants 
and buffer species under fasted state, focusing on BCS II drugs.  These four 
aforementioned GI physiological determinants, and their impact on dissolution of BCS II 




The GI hydrodynamic conditions are highly dependant on food intake and highly 
variable among individuals 2-4.  The gastrointestinal motility that impacts on drug 
dissolution and absorption includes gastric emptying 2,5, and the mixing, segmental 
contractions and propulsive movement in the small intestine 6-8.  The gastric emptying is 
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affected by a number of factors, including the intake volume, calories, viscosity, particle 
size, pH, osmolarity and temperature 2,3,5,9.  Generally, the emptying time is shorter for 
content with characteristics of large volume (≥ 200 mL), low calorie, iso-osmotic, low 
viscosity and higher pH, compared to content with small volume (≤ 50 mL), high calorie, 
hyper- or hypotonic, high viscosity and low pH 2,10.  It was also demonstrated that young 
normal premenopausal women have slower gastric emptying rate relative to age-matched 
men, which is due to a decreased antral contractility as supported by both dynamic antral 
scintigraphy and antroduodenal manometry 11.  The gastric emptying is further 
complicated by the fasted-state migrating motility complexes (MMC).  MMCs exist and 
cycle through three phases, which are motor quiescent period (Phase I, no contraction), 
intermittent contractions (Phase II, slow waves and low intensity) and strong contractions 
(Phase III, house keeping wave) 2,12,13.  The MMC phase III begins in the stomach, and 
propagates to the pylorus, and then increases slowly down through the small intestine at 
fasting state 6.   
The hydrodynamics of the small intestine is more consistent compared to the 
stomach in terms of movement pattern and flow rates.  The dominant motility patterns in 
the small intestine are the circumferential and longitudinal contractions.  The 
circumferential movement mixes the GI contents in radical direction, and the longitudinal 
movement moves the GI contents in the distal direction.  The segmental amplitude 
oscillates between a minimal mean of 9.7 mm to a maximum mean of 20.5 mm for the 
cross section diameter14.  Intestinal motility is regulated by neurological, 
endocrinological and gastrointestinal mechanisms, in addition to food intake 15-17.  In 
fasted state, the flow rate stays mostly between 0 and 2.0 mL/min, with a net average of 
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0.73 mL/min in the jejunum and 0.43 mL/min in the ileum 18.  In the fed states, the flow 
rate increases to a range of 0 - 7.0 mL/min, with an average of 3.0 mL/min and 2.0 
mL/min, respectively 18. 
pH 
In fasted state, the gastric pH is highly variable with a range of pH 1.2 – 8.38 4,19-21.  
It was reported that young Caucasians have gastric pH below 3 under 90% of the fasted 
state, and 25-75% of them within pH range 1.4 to 2.1 22.  In comparison, about 10-20% of 
the same ethnic groups over the age of 65 years have a gastric pH value of 6 or higher, 
and the percentage seems to be even higher for Japanese subjects 23.   
In general, the pH values in the small intestine are higher than in the stomach 24.  
While the pH value in the small intestine is more consistent and much less dependent on 
fasted and fed states, there is an upward pH gradient from the duodenum towards the 
ileum, covering a range of 6.0 - 7.5 25, as shown in Table 1.2.  This pH range is consistent 
with the recent findings from duodenal aspirates.  For example, the median duodenum pH 
value was reported to be 6.2 from twenty healthy human duodenal aspirates 19, and in 
another paper the pH value from twelve pooled human intestinal fluid collected at the 
fourth part of the duodenum at fasted state was found to be 6.7 26.  In jejunum, the pH 
shifts to higher values.  It has been reported that the average jejunum pH values are 6.8 27, 
7.1 21and 7.5 28, at fasted state.   
Bile Salts 
A detailed review of the physical chemistry of bile as it pertains to the physiology 
of GI tract has been published in 1980s 29.  The dominant bile salts are cholate, 
deoxycholate, chenodeoxycholate, and their corresponding tauro- and glycol-conjugated 
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forms 27,30.  The total concentration of bile salts in fasted state stomach is generally low.  
In radiolabeled pool sample, the average bile salts is 80 µM 31.  Gastric fluids collected 
from 36 healthy volunteers showed a range of 0.0 – 2.5 mM, an average value of 0.2 mM, 
with a standard derivation of 0.5 mM 21.  Other researchers reported an average value of 
0.275 mM, while 50% of their samples were not detected with bile salt concentration 32.  
In a most recent study, it was reported that the gastric bile salts concentration at fasted 
state is below the quantification limit, i.e., less than 0.5 mM 19.  These results indicate 
that large variability exists for the gastric bile salt concentrations, partially due to variable 
duodenal reflux among individuals.   
In upper small intestine, the bile salt concentration is generally higher than that in 
stomach.  For example, in earlier studies the average bile salt concentration at fasted state 
was reported to be 4.5-6.4 mM in duodenum, and 5-6 mM in jejunum 33-35.  Later, 
Lindahl et. al. reported a slightly lower average bile salt concentration in jejunal fluids 
was 2.9 mM, with a standard derivation of 2.9 mM 21.  This value is consistent with 
recent studies, such as 2.00 ± 1.92 mM 36, 2.0 ± 0.2 mM 28, 2.6 mM 19, 3.5 ± 1.6 mM 27, 
and 2.82 mM 26, in fasting jejunal fluids.  The literature data indicates that bile 
concentration along the GI tract is generally low at the fasting state.   
An indirect indication of the bile salt contents is surface tension.  The surface 
tension is significantly lower than that of water, i.e., in the range of 33 – 46 mNm-1 in 
fasting stomach, and 28 – 33.6 mNm-1 in upper small intestine 4,19,27,28.  It should be noted 
that a total bile salt concentration of 10 mM may present variation in surface tension 
measurement because of the various compositions of di- or trihydroxy- species in the bile 
salts 37.   
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Buffer Species 
The dominant buffer species in human body fluids, including the gastrointestinal 
fluids, are bicarbonates.  Gastroduodenal bicarbonate has long been known as the main 
buffer system to create a pH gradient along the gastrointestinal lumen 38-41.  It was also 
known that endogenous bicarbonate is mainly transported into the lumen by Na-HCO3 
cotransporters (NBC) through cystic fibrosis transmembrane regulator (CFTR) pathway, 
and partially by paracellular migration depending on intestinal transmucosal hydrostatic 
pressure and motility.  The secretion of bicarbonate into mucus gel provides a near-
neutral pH at the epithelial surfaces in the stomach and duodenum, neutralizing luminal 
acids 42-44.  Bicarbonate concentrations in human GI fluids have been reported to be 
within a dynamic range, depending on the fasted and fed states as well as local regions 
along the GI tract 39,45-47.  For example, as early as 1935, the bicarbonate concentration 
was measured directly from the fasted human duodenum using titration method, and the 
values were reported in the range of 4-21 mM 38,40, with an average of 15 mM 47.  More 
recently, the 
2CO
P in the human duodenum was measured using 
2CO
P electrode in situ with 
perfusion of 154 mM NaCl at 2 mL/min, and then the HCO3- concentration was 
calculated to be mean value of 6.7 ± 0.34 mM at pH 7.22 using the Henderson-
Hasselbalch equation 48.  In the literature of pharmaceutical field, the bicarbonate 
concentration has been expressed indirectly using buffer capacity.  For example, Person 
et. al. 28 showed that the mean value of the buffer capacity of human jejunum at fasted 
state is 2.4-2.8 mmolL-1pH-1, which corresponds to 18.1 mM of bicarbonate 
concentration at pH 7.5 assuming that the buffer capacity is solely attributed by the 
bicarbonate buffer species.  Recently, Kalantizi et al.19 reported the range of buffer 
 7
capacity for distal duodenum of fasted human, which is equivalent to 4.35 – 21.6 mM of 
HCO3- at pH 6.2.  It should be noted that the buffer capacity of the fasting intestinal 
fluids is contributed by not only bicarbonates, but also a very small amount of phosphates 
(0.4 – 1.8 mM from 4 volunteers) 49 as well as endogenous enzymes and amino acids.  
Nonetheless, even though bicarbonate buffer is the obvious choice, it has been rarely 
employed in drug dissolution testing.  
Other Gastrointestinal Factors 
In addition to GI motility, pH, bile salts and buffer species, the transit time along 
small intestine 50-53, the fluid volume 54-56 and splanchnic blood flow 57-59, also impact on 
drug dissolution and/or drug absorption process.  These factors are frequently further 
complicated by liquid or solid intake.   
 
Effects of GI Factors on BCS II Drugs  
BCS II class drugs exhibit characteristics of high permeability and low solubility, 
and their drug solubility or dissolution rate is the rate limiting step in drug absorption.  
This class of drugs includes non-ionizable compounds such as carbamazepine, 
fenofibrate and griseofulvin, and ionizable compounds such as ibuprofen (acid) and 
diazepam (base).   
For non-ionizable compounds, the pH changes along the GI tract would not have an 
impact on drug solubilization or dissolution, whereas the contents of bile salts would 
significantly increase the solubilization thus enhancing its dissolution rate.  Examples are 
griseofulvin 60 and fenofibrate 61.  In the case of griseofulvin, its solubility increased 107-
fold, 31-fold, fourfold, and threefold in the presence of SDS, CTAB, Tween 80, and 
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Cremophor EL.  Dissolution into SDS and CTAB were markedly enhanced as well, with 
about one-third as much as solubility enhancement 60.  The less significantly increased 
dissolution rate relative to solubility is due to a smaller diffusion coefficient of the drug-
loaded micelles 60.  For fenofibrate, its solubility was enhanced approximately 2000-fold, 
and intrinsic dissolution rate was improved about 500-fold, in a pH 6.8 buffer containing 
2% (w/v) sodium lauryl sulfate compared to that in buffer alone 61.  At fasted state, the 
concentrations of bile salts are low, in the range of 2.0-6.0 mM, reported by many 
researchers.  Thus, compared with the fed state, the impact of bile salts on poorly soluble 
non-ionizable drugs is far less significant in fasted state.   
For BCS II weak bases such as dipyridamole (pKa: 5.7-6.4) 62,63 and ketoconazole 
(pKa: 2.94 and 6.51) 64,65, their in vivo solubility and dissolution are more complex 
compared with the weak acids.  BCS II weak bases, with pKb values that could lead to 
ionizing greatly in the gastric acidic environment, would dissolve quickly in stomach.  
Once they enter the duodenum, the extent of ionization is significantly reduced due to 
elevated pH 26,66.  It is very likely that the ionized base form would precipitate at the 
upper small intestine.  The rate and extent of precipitation, and the size and the 
polymorphic form of the precipitates, are controlled by a number of factors such as the 
extent of supersatuartion and solid form of the weak base, and the pH, fluid volume, 
viscosity and bile salts concentration of the duodenum.  The gastric pH appeared to be a 
primary determinant in dipyridamole absorption in the elderly 67.  In 11 healthy subjects, 
the low fasting gastric group was pretreated with or without 40 mg of famotidine, and the 
high fasting gastric group (pH > 5) was pretreated with or without 1360 mg of glutamic 
acid hydrochloride.  In both groups, an elevated gastric pH is responsible for not only a 
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decreased absorption in terms of Cmax and AUC, but also a slower Tmax, in 
dipyridamole 67.  In a recent study, the in vitro dissolution rate and in vivo dog absorption 
of two weak bases, i.e., ketoconazole and dipyridamole, were demonstrated to be pH-
dependant 68.  Particularly, the AUC increased significantly when the gastric pH is 
lowered by pentagastrin pH of 2-3, whereas AUC decreased markedly with an elevated 
gastric pH to 5-7.5 by famotidine treatment.  For ketoconozloe, a 30-fold difference was 
observed between the pengastrin and famotidine groups, and for dipyridamole the 
difference was 9-fold 68.   
For very weak acids with high pKa values such as phenytoin (pKa: 8.06) 69, its 
ionization would be very limited in the stomach as well as along the small intestine, thus 
resulting in the unionized free acid as the dominant form in the GI tract.  For BCS II 
weak acids such as ibuprofen and ketoprofen, with respective pKa values of 4.2 and 4.5, 
which are in the GI physiological range, extensive ionization of these compounds at 
upper small intestine is expected.  This is because the average pH in upper small intestine 
is around 5.8 - 6.5, which is at least 1 unit higher than the drug pKa, increasing the 
apparent solubility of the weak acid by 10 - 100 fold.  Thus, their in vivo solubility and 
subsequent dissolution would be high, presumably behaving more likely as a BCS I 
compound.  However, the combined effects of pH and surfactants on the solubilization 
and dissolution of weak acid drugs has received little attention, especially in view of 
reflecting an in vivo change of pH and surfactant along the gastrointestinal tract using an 
in vitro model.  Therefore, it is important to investigate the effects of pH combined with 
surfactant on the solubility and dissolution of BCS II water-poorly soluble weak acids in 
an in vitro environment.   
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In addition to pH and bile salts, the buffer species, namely, the bicarbonate, is a 
critical factor that significantly impact on dissolution of ionizble drugs, but has been 
overlooked in the past.  As stated previously, bicarbonate is the dominant physiological 
buffer species along the GI tract.  Further, buffer concentration and species have been 
shown to impact on the dissolution of ionizable drugs such as naproxefen.  The intrinsic 
dissolution rate of naproxen increase with the escalation of buffer concentration, which 
was demonstrated consistently in three buffers including phosphate, citrate and acetate 70.  
More interestingly, the work also showed that naproxen demonstrated a decreased 
dissolution rate in the following buffer species: phosphate > citrate > acetate, despite all 
the buffers were maintained at the same buffer concentration and same pH value 70.  
Therefore, it is important to investigate the impact of bicarbonate species, and to evaluate 
the difference between bicarbonate and pharmaceutically commonly used buffer such as 
phosphate, on ionizable drug dissolution.  
It should be noted that the same active species could be synthesized as different salt 
forms, or crystallized as different crystal forms (polymorphs), solvates (pseudo-
polymorphs) and amorphous form.  All of these chemical and physical transformations of 
same active species could have an impact on drug dissolution and absorption, particularly 
for the BCS II drugs.  However, in pharmaceutical industries their development is more 
likely due to the need of creating feasible processes for bulk and formulation 
manufacturing, fulfilling regulatory requirements and extending exclusive marketing 
right via patent.  The API should be distinguished from its drug products.  In the content 
of immediate-release dosage forms, the drug dissolution can still be modified 
significantly by the excipients and/or manufacturing conditions during the formulation 
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processes.  To name a few, manufacturing variables could have an impact on dissolution 
because they could induce changes in crystal forms, surface characteristics, particle size, 
porosity of API and /or drug products 71-74.  For example, particle size reduction is 
frequently used in processing API as well as intermediate drug products to enhance drug 
dissolution/absorption and/or manufacturing feasibility.  It has been reported that the 
diffusional layer thickness is a function of drug particle sizes, which subsequently would 
impact on the drug dissolution rate 74-76.  The dependence of diffusional layer thickness 
on the hydrodynamic conditions that is pharmaceutically relevant such as in a USP 
device or under normal GI motility, however, has been largely ignored.  Furthermore, the 
combined effects of particle size and fluid velocity on diffusional layer thickness have yet 
to be addressed.   
 
Selection of Model Compounds  
The model compounds employed in this thesis are fenofibrate, ketoprofen and 
indomethacin.  The chemical structures and the biopharmaceutical properties of these 
three compounds are showed in Figure 1.1 and Table 1.3, respectively.   
Fenofibrate was selected to investigate the combined effects of particle size and 
fluid velocity on diffusional layer thickness for its non-ionizable and poorly soluble 
nature, and its existence as a single polymorph.  Ketoprofen was chosen to investigate the 
combined effects of pH and surfactants simulating upper small intestine for its pKa value 
within GI physiological range and its poor solubility.  Ketoprofen and indomethacin were 
employed to investigate the effects of buffer species, i.e., bicarbonates versus phosphates, 
owing to their pKa value within GI physiological range and its poor solubility.   
 12
 
Implications of GI Factors in Establishing a Bioequivalence Dissolution 
Methodology 
The purposes of developing a dissolution methodology are to serve quality control 
(QC) or bioequivalence (BE) evaluation 77-79.  The routinely used dissolution testing 
aimed for QC is to ensure that the drug products meet dissolution specifications, comply 
with regulatory requirements, and detect manufacture reproducibility.  The focus of a BE 
dissolution testing is shifted to provide the in vivo performance of a drug product.  Its 
primary goal is to predict in vivo dissolution, and potentially in vivo absorption for highly 
permeable drugs 80.  Therefore, the design of these two dissolution testing are quite 
different.  Ideally, the QC dissolution should be the same or very similar to the BE 
dissolution testing, thus the in vitro dissolution would reflect the in vivo situation, 
because assuring the in vivo quality is the ultimate goal of a drug product.   
Most of the dissolution related literature addresses the needs of QC, and only 
limited research has been invested to design BE dissolution methods.  In establishing a 
meaningful BE dissolution methodology, two very important aspects must be considered: 
the hydrodynamic conditions along the GI tract and the complex contents of the GI fluids.  
The interplay between the GI hydrodynamics and GI fluids present the most challenging 
environment in designing a biorelevant dissolution test.   
The dynamic and heterogeneous fluid velocity of the GI tract induced by GI 
motility remains an obstacle for an accurate simulation of in vivo hydrodynamic 
conditions, despite of several attempts 81-83.  Meanwhile, investigation of the 
pharmacopeial type of dissolution apparatus demonstrates the complexity of fluid 
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velocity profiles in either basket or paddle device 84-87.  Further, a comparison of these 
two results clearly reveals a remarkable gap between the pharmacopeial apparatus 
hydrodynamics and the in vivo physiological hydrodynamics.  The geometric, kinematic 
and dynamic factors in the pharmacopeial apparatus are very different from those along 
the in vivo GI tract.  Therefore, the USP apparatus such as the type II paddle apparatus is 
suitable for QC purpose monitoring the mass transport of API from the dosage forms.  
However, it is much less relevant in assessing the in vivo performance of a drug product.  
Even though the USP dissolution apparatus II has been most widely employed in 
checking the release profiles of drug products, fundamental understanding of how the 
drug particles and fluid velocities are combined to impact on drug dissolution has yet to 
be explored.  For example, in the original Noyes-Whitney equation 
( )s t
dM D A C C
dt h
= − − , the dependence of h  on drug particle size and paddle speeds 
have never been investigated quantitatively in a USP dissolution apparatus II.  Many 
dissolution models assume h  to be a constant, or comparable with particle radius.  This 
simple assumption is convenient; however, it has not been supported by any direct 
experimental data.  In addition, such an assumption is contradictory to a basic fluid 
dynamic principle, i.e., the apparent diffusional layer thickness is altered by 
hydrodynamics.  Even though a USP dissolution apparatus II is well-defined, the fluid 
velocity is clearly changing with the paddle speeds.  Thus, a changing apparent h  with 
paddle speeds is foreseeable and an alternation of h  therefore reciprocally affects the 
dissolution rate.   
The equally important consideration in designing a BE dissolution test is the 
selection of appropriate dissolution medium.  Dissolution media mimicking the in vivo GI 
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fluids has attracted numerous interests and achieved significant progress in the past 
decade.  The earliest proposal is found in the paper discussing pH-partition hypothesis to 
estimate drug absorption by Dressman et al. in 1985 88.  Later, the historical paper by 
Amidon et al. enabled further enhancement of biorelevant media under the frame of 
Biopharmaceutics Classification System (BCS) 1.  In 1997 characterization of fluids from 
stomach and upper jejunum in healthy fasted-state volunteers was conducted 21.  In 1998 
based on human GI physiology, the milestone paper by Dressman et al. provided the 
insightful and comprehensive initiatives in designing dissolution medium mimicking in 
vivo GI fluids 4.  More recently, solubility and dissolution of neutral and ionizable weak 
acids and bases were investigated in human, canine, and simulated fluids.  The major aim 
of these studies is to investigate how drugs with various properties would dissolve under 
normal GI conditions, in human, dog and simulated biorelevant media 19,26-28,36,89.  
Almost all these studies focused on pH, osmolality and bile acids.  However, the 
intuitively physiological buffer, i.e., bicarbonate buffer, as well as its impact on drug 
dissolution, has been rarely investigated 90.  Gastroduodenal bicarbonate has long been 
known as the main buffer system maintaining a pH gradient along the gastrointestinal 
lumen 41.  As a predominant buffer in human gastrointestinal physiology, bicarbonate has 
been overlooked in drug dissolution testing.  Most published studies use phosphate or 
acetate buffers instead, creating a disconnect between the physiological buffer species 
and the buffer species used in in vitro dissolution studies, including the simulated GI 
fluids.  To this date, there has been few experimental data or theoretical derivation 
pertaining to bicarbonate buffer as a dissolution medium.  In literature, it has been 
reported that the concentration and buffer species significantly impact on dissolution 
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rates of ionizable drugs even at the same pH value 70,91,92.  Thus there is a need to 
characterize the dissolution properties of bicarbonate buffer and compare them with those 
of the more often–used buffer systems.  In order to mimic the in vivo source of 
bicarbonate, an external supply of CO2 is necessary to maintain the bicarbonate in the in 
vitro dissolution media.  For example, this can be achieved using purging CO2 gas into 
the dissolution media sustaining a partial CO2 pressure through the testing.   
 
Summary 
In summary, the two essential aspects that must be considered in order to mimic in 
vivo situation and to design meaningful BE dissolution, are the GI hydrodynamics and GI 
fluid contents.  The GI motility determines how fast the drug is entering the duodenum 
and jejunum, how long the drug is staying in the small intestine, and how dynamic a drug 
particle is interacting with the GI fluids.  Chapter 2 of this thesis deals with the combined 
effects of drug particle size and paddle speed on diffusional layer thickness of a poorly 
soluble drug, fenofibrate, in a USP dissolution apparatus II.  The GI fluid contents not 
only determine the drug solubility but also the drug dissolution rate along the GI tract.  
Among various GI fluid factors, chapter 3 focuses on the combined effects of pH and 
surfactants on a poorly soluble and ionizable weak acid, ketoprofen, under normal 
conditions in the upper small intestine.  Further, chapter 4 examines the impact of buffer 
species, particularly the physiological bicarbonates versus pharmaceutical phosphates, on 
weak BCS II acids such as ketoprofen and indomethacin.   
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Specific Aims: (1). To determine the combined effects of particle size and fluid 
hydrodynamics on diffusional layer thickness of a poorly soluble drug, fenofibrate.  (2). 
To investigate the solubilization and dissolution of a poorly soluble and weakly acid, 
ketoprofen, under the conditions mimicing the pH and surfactants along small intestine.  
(3). To compare the pharmaceutical phosphate buffers with physiological bicarbonates in 
dissolution of BCS II weak acids, ketoprofen and indomethacin.   
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Table 1.1.  Biopharmaceutical Classification System (BCS). 
 
BCS class I: 
High solubility 
High Permeability 
BCS class II: 
Low solubility 
High Permeability 
BCS class III: 
High solubility 
Low Permeability 







Table 1.2. pH in the small intestine in healthy humans in the fasted statea.   
 
Location Fasted state pH 






Ileum  6.5 
 6.8-8.0 
 7.4 








Fenofibrate Ketoprofen Indomethacin 
Intrinsic solubility 
in water at 37°C 
< 0.3 µg/mL  0.253 mg/mL 2.43 µg/mL 
Permeability (cm/s) ClogP: 3.86 a8.7×10-4 b3.4×10-4 
Diffusivity (cm2/s) 7.15×10-6 9.3×10-6 8.0×10-6 
pKa Non-ionizable 4.76 4.17 
Maximum  
dose (mg) 
200 75 50 
Provisional BCS 
classification 









a: human jejunum permeability 
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PARTICLE DIFFUSIONAL LAYER THICKNESS IN A USP DISSOLUTION
APPARATUS II: A COMBINED FUNCTION OF PARTICLE SIZE AND 
PADDLE SPEED
Abstract
This work was to investigate the effects of particle size and paddle speed on the 
particle diffuisonal layer thickness happ in a USP dissolution apparatus II.  After the 
determination of the powder dissolution rates of five size fractions of fenofibrate,
including < 20, 20-32, 32-45, 63-75 and 90-106 m, the present work shows that the 
dependence of happ on particle size follows different functions in accordance with the 
paddle speed.  At 50 rpm, the function of happ is best described by a linear plot of 
9.91 23.31apph d  ( ) throughout the particle size range of 6.8-106 m.  In
contrast, at 100 rpm a transitional particle radius of 23.7 m exists, under which linear 
relationship  ( ) occurs, but above which h
2 0.98R
1.59apph r
2 0.98R app becomes a constant of 
43.5 m.  Thus, happ changes not only with particle size, but also with the hydrodynamics 
under standard USP configurations, which has been overlooked in the past.  Further, the 
effect of particle size and paddle speed on happ was combined using dimensionless









( ), was observed.2 0.9875R
Introduction
The Biopharmaceutics Classification System (BCS) categorizes drugs into four 
classes according to their solubility and permeability.1  The BCS II class of compounds
exhibits high permeability and low solubility relative to the administered dose.  For a
BCS II drug formulated into an immediate release (IR) dosage form, the combination of 
high drug permeability and adequate GI transit time will lead to a rate and extent of oral 
absorption that is controlled by the in vivo process of drug dissolution.1,2
Mechanistically, one of the fundamental issues in modeling and understanding 
dissolution is to determine the relationship between the diffusional layer thickness (happ)
and particle size under a defined set of hydrodynamic conditions.  In the past, the Noyes-
Whitney equation ( )s t
dM D A C C
dt h
has been widely used to describe drug particle 
dissolution,3 where h is a thin static liquid layer at the solid surface under steady state
conditions.  For the past half century, the Noyes-Whitney equation has served as the 
theoretical basis for many classical dissolution models that assumed various relationships 
between the drug particle size and happ.  For example, happ was assumed to be a constant
by Hixson and Crowell,4 while Higuchi and Hiestand5-7 proposed that it was 
approximately equal to the radius of the particle, and Niebergall et al.8 determined it to be 
equal to the square root of the particle radius.  All of these assumptions imply that the 
correlation between happ and particle size is applicable to all particle size ranges.  In 
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recent years, this correlation has been advanced by hypothesizing the existence of a
transitional particle size, above and below which happ behaves differently depending on 
the magnitude of the drug particle radius.  For example, using intrinsic dissolution studies 
from rotating disks, Hintz and Johnson9 proposed that 30 m was the critical particle
radius.  Specifically, their model stipulates that the value of h is a constant 30 microns
for particles with radii larger than 30 microns, while for particles less than 30 microns h
functions as a thickness equal to the particle radius.  However, this assumption is based 
on a rotating disk hydrodynamic system, uses a compressed tablet, and powder size plays 
no role.  Thus, this assumption needs to be verified with powder dissolution testing using 
various particle sizes.  Further, such an assumption is contradictory to a basic fluid 
dynamic principle, i.e., the apparent diffusional layer thickness is often altered by 
hydrodynamics.  Recently, Nystrom and colleagues used a Coulter Counter to directly 
measure particle size and concluded that a critical diameter of 15 m existed for
griseofulvin and oxazepam, below which the happ decreased substantially with decreasing 
particle size.  The effect of particle size on happ became less significant when particles 
diameters were above 15 m.10  More recently, employing the same particle size
measuring technique, Figueiredo et al. concluded that the critical particle size should be 
22 m for ibuprofen, where the value of h was linearly proportional to particle diameter
( ) when the diameter was less than 22 m but was a constant ( ) when the particle 
diameter was above 22 m.
kd crikd
11
In the previously reported studies, even though the dependence of happ on particle
size has been mathematically described, its dependence on the dissolution hydrodynamics 
has received very little consideration. Therefore, a complete examination of happ as a 
29
function of particle size and pharmaceutically relevant hydrodynamics is theoretically





     (1)
where is the drug particle diameter, is the linear velocity of fluid in cm/s,d 0v  is the
kinematic viscosity (cm2/sec) of the fluid, a  and are parameters that can be estimated









   (2) 
where is mass transfer rate cm/s, and D is the diffusion coefficient of the drug 
molecule cm
k
2/s.  As early as 1952, Eq 2 was theoretically derived and experimentally
validated by Ranz & Marshall to describe the rate of evaporation of pure liquid drops and 
water drops containing dissolved and suspended solids, such as in spray-drying 
operations.12,13  In a subsequent article published in the same year, Ranz extrapolated his 
theory to mass transfer of single particles and packed beads.14  In 1954, F.H. Garner and 
his colleagues applied this theory to dissolution from a fixed solid sphere in fluid flow.15
Specifically, they found that the dissolution of benzoic acid in a stream of water was







kd .  In 1960, Bird elaborated the Ranz-Marshall 
equation to describe simultaneous heat and mass transfer of a liquid or solid sphere under 
forced convection.16  In 1962, Harriott applied Eq 2 for depicting mass transfer of 
benzoic acid, boric acid, zinc and lead sulfate particles suspended in agitated and baffled 
tanks.17  More recently, Fogler et al. employed Eq 2 to study the dissolution of poly-
30
dispersed particles.18  Drug powders dissolved in a USP dissolution apparatus II would 
encounter a similar hydrodynamic environment to that investigated in Harriott and 
Fogler’s studies: that is, mass transfer from solid spheres under forced convection.
In this paper, fenofibrate was selected to serve as a model BCS II drug.  Selection 
of USP II conditions is pharmaceutically relevant and of particular importance from a 
regulatory perspective.  Moreover, five size fractions were utilized in the current study to
further characterize and understand the impact of particle size on happ.  The focus of this 
work is to: 1) determine the diffusion layer thickness happ for a BCS II model drug, 
fenofibrate, in a USP dissolution apparatus II; and 2) illustrate the dependence of happ on 







Calculation of Diffusional Layer Thickness happ
The diffusion layer thickness happ of drug particles in a USP dissolution apparatus II 
can be calculated based on their dissolution rates.  At dissolution time zero, the initial
weight of a single drug particle is 30
4
3 v0,




M r , where  and  are the volume particle radius at time zero and 
t, respectively.
0,vr ,t vr







      (3)
where is the total number of particles, is the drug concentration at time t, and V is
the dissolution volume.  In addition, the Noyes-Whitney equation was originally derived
N tC
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in the slab coordinate.  When it is applied to a spherical particle using spherical
coordinate, it can be rewritten as 19,20:
1 1( )(S t
app
dM DA C C
dt r h
)     (4)
Eq 4 can be simplified to the following:
( ) 1 1(t S t
t app
dr D C C
dt r h
)      (5)
where is the density of drug particles, is the drug solubility in the dissolution
medium, and h
SC
app is the apparent diffusion layer thickness.  Thus, with known parameters 
including , ,SC tC , ,  and , the relationship between  and  can be
established, the derivative of which is connected to through Eq 5. 
V D N tr t
apph
For a system that is approximately spherical, Eq 4 is still valid.  However, in the
case of non-spherical shape, the particle mass M should be related to the particle volume
radius , and the particle surface area vr A should be related to the particle surface radius
sr .  The volume radius can be measured directly by Coulter Counter method.  The 
surface particle radius is calculated using equation , where the surface area 
vr
24 srA A  is
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, is defined as the shape 
factor.  This ratio is a fundamental property related to the particle dissolution rate in 
addition to drug solubility and diffusivity that are the essential factors dictating the 
diffusion and convection within the solid-liquid interface.  The dissolution of an 
individual particle presumably proceeds in an isometric manner at the initial stage of the
dissolution test.  Therefore, the shape factor could be assumed as a constant in calculating
the  values.  Eqs 3 and 7 are employed in calculating .apph apph
Dependence of happ on Particle Size and Fluid Velocity 
The diffusion layer thickness for drug particles in a particular geometry is a 
function of drug properties including particle diameter d  and diffusivity , and fluid 
properties of fluid velocity 
apph
D
0  and kinematic viscosity .21
0( , ; , )apph f d D       (8)
Therefore we have  variables for  of drug particle dissolution in a USP vessel.
These  variables are built up from
5n apph
5n 2k  independent dimensions that are: length L
(cm) and time T (s).  According to the -theorem, the variables 5n  can be reduced to 3 
independent dimensionless numbers, which are defined as app
h
d
, Reynolds number 
0
Re d  and Schmidt number ChS D
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Most of previous work, both theoretical and practical,12-15,17,18,22 suggested the form of: 




     (10)
In the current case, the kinematic viscosity of dissolution medium  and drug diffusivity 
of fenofibrate  are constant, thus equation 1 arrives.D
0
1/ 2 1/ 2a+b (Re) ( )app
h dva b
d
    (1)
where and are constants and can be determined using regression analysis of the 




Materials and Preparation 
Fenofibrate (> 99% purity), sodium lauryl sulfate and all other chemicals were of 
analytical grade and were purchased from Sigma Chemical Company (St. Louis, MO). 
Distilled, deionized and filtered water was prepared in house and used for all
experiments.  Fenofibrate “as received” from Sigma had a broad size distribution, with 
which four size fractions, i.e., 20-32, 32-45, 63-75 and 90-106 m were obtained by 
sieving.  In brief, the bulk material was initially dry sieved through the USA standard test 
sieves (Newark Wire Cloth Company, Clifton, NJ).  Then, 300 mg of the dry sieved 
fractions were well suspended into 60 mL of 0.9% NaCl solution containing 0.05% SLS, 
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and the suspensions were wet sieved through the same standard sieves.  The wet sieved 
fractions on the sieve were rinsed with 0.9% NaCl solution containing 0.05% SLS and 
subsequently with water, and then they were dried overnight in a vacuum oven at 30 C.
The < 20 m size fraction was achieved by jet-milling the bulk material as received from
Sigma.  About 100 g of fenofibrate bulk material was jet-milled through a lab scale size 
fluid energy grinder (Sturtevant Inc., Hanover, MA) that was operated using compressed
nitrogen, with an approximate yield of 95%.  The milling air setting was 60 – 70 PSIG, 
and the feed air pressure was operated between 90 – 100 PSIG.  The crystal form of the 
jet-milled fenofibrate was also characterized using powder X-ray diffraction (PXRD) and 
differential scanning calorimetry (DSC) to confirm the absence of amorphous material
and process induced changes in crystal form.  All the five fractions of particles were fully
characterized with regards to their specific surface area, particle volume diameter,
number diameter, and density.  The USP pH 6.8 50 mM phosphate buffer without 
pancreatin was prepared following standard procedures.23  Piecewise regression analysis
and parameter estimations were performed using Sigmaplot 10.0 (SPSS Inc., Chicago, 
IL).
Powder X-ray Diffraction (PXRD)
Powder diffraction patterns of jet-milled and “as received” fenofibrate were
recorded with a Scintag X-ray diffractometer (Franklin, MA) using CuK  radiation (  = 
1.54 Å), tube voltage of 40 kV, and tube current of 20 mA.  The intensities were 
measured at 2-theta values from 5° to 40° at a continuous scan rate of 5° /min.
Differential Scanning Calorimetry (DSC)
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The thermal behavior of jet-milled and “as received” fenofibrate were studied using 
a TA Instruments 2920 modulated DSC (TA Instruments, New Castle, DE) with 
refrigerated cooling system (RCS) in standard mode.  Approximately 5-10 mg samples
were weighed into aluminum DSC pans, crimped, equilibrated to -80°C and then heated 
up to 100°C at speed of 5.0°C/min, with nitrogen purge at 110 mL/min.
Particle Size Determination
The mean volume particle size diameters for all size fractions were determined
using the Coulter Counter (non-laser light scattering) method.  The jet-milled material
was first suspended in the 0.9% NaCl solution containing 0.25% SLS, saturated with 
fenofibrate.  Then the suspension was quickly transferred into the 0.9% NaCl solution 
containing 0.1% SLS and saturated with fenofibrate, which served as the suspending 
medium and testing electrolyte for all samples during particle size measurement.  It 
should be emphasized that the diameter given by the Coulter is a volume equivalent 
diameter, namely, , where v is the particle volume directly measured by 
the Coulter.
3/1)/6( vdv
Specific Surface Area Measurement
The specific surface area of fenofibrate powders was determined at liquid nitrogen
temperature using BET methodology employing nitrogen as the adsorbate.  The surface 
area was used to calculate the particle surface radius by equation 24 sA r .
24
Solubility Measurement
The aqueous solubility of fenofibrate was measured at 37ºC in 0.25% SLS pH 6.8 
phosphate buffer, instead of water.  Since SLS has a CMC of 0.25% (w/v) in water, it 
serves as a reasonable surrogate of the in vivo surfactant properties provided by bile salts 
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and provides the necessary enhancement in solubility and dissolution rate for fenofibrate 
that is practically insoluble in water with a solubility of < 0.3 g/mL.  Fenofibrate 
solubility was determined by suspending excess fenofibrate powder in 5 mL buffer in a 
screw-capped vial.  The suspension was equilibrated by shaking in an orbital shaker
water bath (LABLINE Instruments, Inc., Melrose Park, IL).  At suitable time intervals,
1.0 mL of aliquots were drawn and filtered through 0.45- m membrane, and then diluted 
with an appropriate amount of phosphate buffer prior to the spectrophotometric assay at 
= 292 nm using a UV spectrophotometer (Beckman Coulter DU 650, Fullerton, CA). 
The equilibrium solubility of fenofibrate was established when the difference between 
three consecutive measurements is within 1%, a process that may take up to 7 days.
Dissolution Profiles in USP Dissolution Apparatus II 
The dissolution profiles of various size fractions of fenofibrate were measured in a 
USP dissolution apparatus II at 37 C using pH 6.8 phosphate buffer containing 0.25%
SLS.  For the jet-milled fenobibrate, 50 mg powder was weighted into a 1.0 mL of 
eppendorf tube, then 0.5 mL of the dissolution medium were added, and then the 
suspension was sonicated at low power for 5 seconds.  The well dispersed jet-milled
suspension was then immediately transferred into the prepared dissolution vessel, and 
rinsed with the dissolution medium three times 5 mL each.  The four bigger size fractions 
of fenofibrate powders (50 mg) were directly dropped into the 37ºC 500 mL dissolution 
medium that was previously degassed.  For the Dissolution experiments were conducted 
in triplicate at both 50 rpm and 100 rpm for each particle size.  Aliquots were drawn at 
0.33 – 1 min intervals, filtered through 0.45- m membrane and diluted if necessary prior
to UV spectroscopic analysis at  = 292 nm (BeckmanCoulter DU 650, Fullerton, CA).
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Results
Characterization of Fenofibrate Particles
As evident from the DSC traces of the jet-milled and “as received” fenofibrate 
(Figures 2.1a and 2.1b), a negligible glass transition occurs around -45 C with a very 
small enthalpy of -0.0015 w/g, followed by the melting point around 79.5 C with an
enthalpy of fusion of approximate 95 J/g.  This DSC result indicates that no significant
changes in crystal forms or amorphous content were introduced through the jet-milling
process.  These results are further confirmed by PXRD (Figure 2.2) where the slightly 
decreased peak intensities are consistent with a reduction in particle size.
The volume particle size distribution of each size fraction is shown in Figure 2.3,
and the surface area equivalent particle radius, shape factor and density for each size 
fraction are summarized in Table 2.1.  Visual observation via SEM shows the irregular 
and multi-sided morphology of fenofibrate particles (Figure 2.4), suggesting that 
fenofibrate particles would dissolve in a relatively isometric manner.
The diffusivity of fenofibrate was calculated as 7.4 10-6 cm2/s using the ADMET 







.25  This value is consistent with the literature reported
experimental value of 7.15 10-6 cm2/s using the rotating disk method.26
Dissolution Profiles of Fenofibrate
The solubility of fenofibrate was determined to be 150.4 ± 1.4 g/mL in 0.25% SLS 
50 mM pH 6.8 phosphate buffer.  The dissolution profiles of fenofibrate particles at 50 
rpm and 100 rpm are shown in Figure 2.5.  Several elements can be drawn from these 
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dissolution profiles.  First, as expected, the dissolution rates increase with decreasing
particle sizes in the following order: jet-milled material (< 20 micron) > 20-32 > 32-45 > 
63-75 > 90-106 m size fractions.  This observation is consistent with the larger surface
area per unit weight of the smaller particles.  Secondly, the dissolution rates of the jet-
milled material are similar at the 50 rpm and 100 rpm.  Finally, the four larger size 
fractions of fenofibrate dissolve faster at a paddle speed of 100 rpm than at 50 rpm,
presumably due to the higher fluid velocities at 100 rpm that lead to thinning of  and 
subsequently more efficient mass transfer. 
apph
Dependence of Diffusional Layer Thickness on Hydrodynamics and Particle Sizes 
The dependence of on particle size and hydrodynamics/fluid velocity were 
examined and illustrated in the two following ways.  The first approach is bifunctional
analysis demonstrating as a function of r under different paddle speeds, as shown in 
Figure 2.6.  This approach determined the transitional particle size through which the
value of exhibits a different correlation with particle radius.  Determination of 




9-11  The second 
approach is dimensionless analysis using Eq 1, investigating the combined effects of 
particle sizes and paddle speeds on .apph
Bifunctional analysis: The transitional particle size for fenofibrate in a USP 
dissolution apparatus II is fluid velocity dependant.  Using piecewise regression, the 
transitional particle sizes are 37.7 ± 5.4 m ( ) and 23.7 ± 0.6 m
( ), under 50 and 100 rpm, respectively (Figure 2.6).  For drug particles 





particle radius.  The linear slopes vary with paddle speeds, and the values are 1.71 (R2 =
0.9872) and 1.59 (R2 = 0.9828), at 50 rpm and 100 rpm, respectively.  In comparison, for
drug particles larger than the transitional sizes, at 100 rpm a constant  was observed
with an approximate value of 43.5 m for any particles with radius larger than 23.7 m;
and at 50 rpm the value continues to increase with particle size but at a slower rate. 
The bifunctional analysis also leads to the plot of  versus 
apph
apph
apph d , as shown in Figure 2.7.
Evidently, at 50 rpm demonstrates a linear correlation with apph d , i.e.,
9.91 23.31apph d , , throughout the tested particle size range 6.8-106 m
in this work.  Whether this linear relationship applies to particles in near-micron or sub-
micron range needs further research, partially due to the complex microfluid dynamics
surrounding these very small particles.  In comparison, at 100 rpm the linear relationship 
transforms into plateau for larger particles.  This dependence of  on 
2 0.9769R
apph d  was then
further exploited in dimensional analysis.





, the Re  number
0
(dv ) was calculated using drug particle diameter d (cm), linear fluid velocity 
(cm/sec), and kinematic viscosity 0v of dissolution medium ( ) at 
37ºC.
2 20.758 10 /cm s
27  The linear velocity of fluid/dissolution medium in an agitated USP vessel 
depends on the rotational speeds of paddle and the location in the vessel.  In addition, the 
use of the linear velocity of the fluid is not convenient in practice, and the rotational 
speed of the paddle is readily available and can be easily adjusted to the linear
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velocity through paddle diameter d , i.e., 0 dv .  It therefore lends to the 
calculation of the Reynolds number using , i.e., dd .  The relationship between 
apph
d
 and d  is proposed in equation 11: 
1/ 2 1/ 2constant( ) ( )app
h d da d a b
d
  (11) 
where eR  is calculated based on the following:  is the particle diameter in m,d  is the
rotational speed of paddle in rpm, is the kinematic viscosity of dissolution medium in
cm2/sec, and the diameter of the USP paddle ( d ) is included in the parameter  (Eq 11).
Figure 2.8 demonstrates that the of suspended drug particles in the USP vessel can 






a two-regional dependence on particle Re, i.e., 1/ 2( )d .  One region is linear, where the
particle Re is  592, and is described by 41.5207 9.25 10 ( )app
h d
d
1/ 2 .  Assuming
the drug diffusivity is ,scm /1015.7 26 26 this regression corresponds to an 
( ), and estimates the values of a = 1.5207 ± 0.0417 and b = -9.25 10
2 0.9875R
0.0001P -4 ± 
4.66 10-5.  The other region describes the relation for particles with smaller Re  number
(either smaller particle size and/or slower paddle speeds), the relationship between app
h
d
and may be more complex.Re
Discussion
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Calculation of Diffusion Layer Thickness happ
Due to its mathematical simplicity, a spherical shape is the best contour to select to 
experimentally determine the value of happ, an approach that was elaborated by Wang and 
Flanagan.19,20  Numerous attempts to prepare spherical and crystalline fenofibrate
particles for this study were unsuccessful because fenofibrate either forms amorphous
spheres or crystalline needles following recrystallization processes as confirmed by 
polarized microscopy.  Therefore, irregular shapes of fenofibrate particles were employed
here with consideration given to their shape factor; that is, the ratio of particle surface
radius to volume radius.  Here, it is assumed that drug particles would dissolve in an 
approximately isotropic manner, implying that the shape factor would remain unchanged. 
This assumption has been used widely in the past, when the shape factors were 
considered constant, as in the initial stages of the dissolution testing.  Even in the case of 
dissolving crystals with a high degree of non-isometricity sharp edges such as needles 
and plates, the shape factor has been reported to change insignificantly until considerable
dissolution occurs.28,29  In addition to the shape factor, the quantity of amorphous content, 
may also contribute to non-isometric dissolution.  PXRD and DSC results confirmed the 
absence of detectable amorphous form for the jet-milled material.
The thickness of a hydrodynamic boundary layer is often defined as the distance 
from the surface of the solid to the point where the tangential velocity attains a value of 
90% of the main stream.21  In general, this layer thickness is not easily evaluated from
experimental work except under well-defined hydrodynamic conditions as in the case of 
the rotating-disk.21 In this work, the is calculated using Eq 7 to describe the distance 
over which the diffusion process dominates the mass transfer.  As such, it reveals the 
apph
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drug dissolution in terms of how resistance to mass transfer may occur in the solid-liquid 
interface in a simple model. In addition, the diffusional thickness can often be used to 
predict changes in mass transfer caused by factors such as chemical reactions.30,31  It is
important to note that the determined in a USP dissolution apparatus is an apparent 
averaged value from all particles under specific hydrodynamic conditions, because the
local environment of fluid dynamics surrounding each individual drug particle is not the 
same throughout the USP dissolution apparatus II vessel.
apph
32-36
Dependence of happ on Hydrodynamics and Particle Sizes
Bifunctional analysis with transitional particle sizes
Dissolution phenomena have been studied in a quantitative manner for more than a
century, during which various relationships between happ and particle size have been 
proposed.5,8-11  Bifunctional analysis of fenofibrate dissolution data suggests that 
Higuchi-Hiestand’s assumption5,6 and Hintz-Johnson’s hypothesis9 appear to be valid, 
only if the powder dissolution occurs under specific hydrodynamic conditions.
Higuchi-Hiestand assumed that happ was equal to or greater than the particle radius, 
and conducted their experiments with 2.2 mg of micronized methylprednisolone (  25 
m) in 100 mL of water in bottles that were rotated at 6 rpm at 25°C.5-7  In comparison
with their work (Table 2.2), the current study experimentally demonstrates that in a USP 
dissolution apparatus II happ may be equal to or greater than particle radius r , only if the 
specific hydrodynamic conditions are provided. The first observation is based on the data 
that at paddle speed of 100 rpm, the particle radius r 44.6 ± 0.4 m is not significantly
different from the corresponding happ value of 43.5 ± 11.2 m.  The second point was
observed at both paddle speeds.  For example, at 50 rpm happ is equal to 1. , and the 71r
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value of happ decreases to 1.59  at a higher paddle speed of 100 rpm, both suggesting that 
h
r
app could be greater than particle radius.
The description of happ as a function of particle size under both paddle speeds was 
compared with Hintz’s work as well, as shown in Table 2.2.  Both sets of data 
consistently demonstrate the existence of a transitional particle size Cr in the 30 m size 
range, and a linear relationship between happ and r when particle size is below .
When particle size is above C
rC
r, a constant happ value, however, was observed at 100 rpm.
Further, despite the similar observations, it is evident that distinct differences exist 
between the Hintz-Johnson’s assumption and our work in the following specific aspects:
1) the value of Cr; 2) the linear slope value between the happ and r ; and 3) the value of 
constant happ.  This difference is attributed to the differences in hydrodynamic conditions
under which the dissolution studies are conducted.  In Hinz-Johnson work, the apph r
assumption was suggested based on a rotating disk system, where a planar constant 
surface area pertains rather than a powder dissolution of spherical geometry where more
complex hydrodynamics pertains.  For example, based on Levich’s equation 
1/3 1/ 21.61( ) ( )Dh 21, a diffusivity of fenofibrate as 7.15 10-6 cm2/s and kinematic
viscosity of the dissolution medium as 7.58 10-3 cm2/s at 37 C, for fenofibrate, a 
rotational speed of 21 rpm would give a h equals to 30 m.  Clearly, the dissolution 
hydrodynamics in these two systems are very different.
Dimensionless analysis
The key dissolution variables employed in Eq 1, particle size and Reynolds number
that is an indicator of the fluid dynamics, were compared to the previous utilization of the 
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Ranz-Marshall equation (Eq 2) as shown in Table 2.3, and the similarities and differences
are discussed as follows.  In Ranz’s original work on mass transfer of single particles and 
packed beds,14 the theory was applied to particle sizes in the range of 0.06 cm to 1.1 cm
and number ranging from 2 to as high as 10eR
5.  In later studies, the particle size varied 
from 15 to 1270 m, and the number ranged from 1 to 10eR
5 (Table 2.3).  Comparably,
the number under standard USP dissolution conditions such as 50 and 100 rpm is 
within the range tested in the original Ranz theory
eR
eR
12-14 and other work.15,17,18,22,37 The
number in a USP dissolution apparatus II encompass a considerable range from a 




dR , the maximum numbers can be determined as 2.9×10eR
4 and 5.8×104 at 50 
rpm and 100 rpm, respectively,33 where is the rotational speed of the paddle,  is the
diameter of the paddle, and 
d
is the kinematic viscosity of the fluid.  Although the mean
particle size in this work, 32 - 106 m, is generally smaller than that utilized by Ranz’s 





could be extrapolated with remarkable accuracy to the particle size
range beyond the Ranz’s.
Industrial Significance of apph
Dependence of  on paddle speeds and particle sizeapph
Dimensionless analysis demonstrated a bipartite behavior of the dependence of 
on paddle speeds and particle size, which may be contributed by several factors.  First, 
apph
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crystal defects and roughness on the particle surface represent a larger percentage of the
crystal weight after milling, since the surface area to volume ratio is increased.  These 
effects were observed to have a significant impact on dissolution rate for particles with 
diameters in the micron range. Second, at small particle sizes, turbulence in the form of
microeddies begins to play a more important role in the hydrodynamics near to the
dissolving surface, in other words a microenvironment different from the bulk 
hydrodynamics is created.38-40  It is also thought that the effective eddy diffusivity of drug 
molecule in the turbulent fluid may be very different from that in bulk fluid.41  Surface 
roughness, crystal defects and microeddies would lead to a faster dissolution rate than 
expected using surface area and the bulk fluid velocity.  This region of small Re  number
merits further research.
Eq 11, 1/ 2( )app
h da b
d
, was also applied to in vitro dissolution behavior of 
other drugs including digoxin and oxazepam independently reported by Nyström et
al.10,42  In their studies, dissolution rates were measured with two different particle sizes
under three rotational speeds, i.e. 350, 500 and 800 rpm.  Dissolution rate data for 
digoxin fit the following the relationship: 
1/ 222.17 0.012( )app
h d
d
 with the 0.9403sqR ( 0.0052)P
For oxazepam,  conforms to the following equation:apph
1/ 23.05 0.016( )app
h d
d
 with the 0.9472sqR ( 0.0063P ) .
The successful fitting of digoxin and oxazepam dissolution data into the function form of 
Eq 11 further supports the linear correlation between app
h
d
 and 1/ 2( )d and its use to 
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estimate values for drug particles in the standard USP dissolution II apparatus, based
on the measured particle size and the rotational paddle speed 
apph
d .
apph  for poorly soluble drugs
Recent estimates suggest that the percentage of BCS II drugs in the top US 200 oral 
IR products is greater than 25%.43  Probably as a result of the widespread application of 
combinatorial chemistry and high-throughout screening activities during the drug 
discovery process,44,45 this percentage will probably continue increase.  To ensure
satisfactory oral absorption, particle size reduction has been widely used to increase the 
surface to volume ratio and thus improve the dissolution rate of poorly soluble drugs.
The current work clearly reveals that the  values generally decrease with decreasing
particle size (Figure 2.6).  Therefore, an increase in the dissolution rate resulting from a 
particle size reduction process is attributed not only to an increase in the surface area to
volume ratio, but also to a decrease in , an important contribution that is rarely
addressed in the literature.
apph
apph
In addition, since the layer thickness depends on the drug diffusivity D , the
corresponding for two drug substances with different D values would be expected 
to be different.  However, it is likely that the would only change slightly because: 1) 




21, is only dependent to the one-third power on D  i.e.apph
2/13/1 )()(61.1 Dh and 2) drug diffusivity of most small drug molecules is low and in 
the range of 10-6-10-5 cm2/s.
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Furthermore, the results in this paper suggest the following: 1). for drug particles 
with radius in the range of 3.4- 23.7 m, is approximately 1.5-fold of particle radius 
(Figure 2.6).  2). under the paddle speed of 50 rpm, the diffusional  exhibits a linear




Finally, Figure 2.6 suggests that for small drug particles, is not significantly 
different under 50 and 100 rpm.  The exact size range for the small particles, where 
is independent of paddle speeds in a USP dissolution apparatus II, is yet to be determined.
In this work, the jet-milled fenofibrate with a mean  of 3.4 m, demonstrates that its 
is independent of fluid velocity.  In the case of cilostazol, the size limit could be in 
the low micron range, i.e., 13 m.  Cilostazol is a poorly soluble compound with a water 
solubility of 6.25 g/mL at 37 C.  Three size fractions with mean particle sizes of 13, 2.4 
and 0.22 m were prepared using techniques hammer-mill, jet-mill and spray-drying,
respectively. In vitro powder dissolution profiles of 5 mg of these cilostazol samples, in 
900 mL of water, FaSSIF and FeSSIF at 37 C in USP apparatus II, were equivalent at the 





46.  This result indicates that the is independent of 
paddle speeds when the cilostazol particles are smaller than 13 m.  Both results suggest
that the hydrodynamic considerations are important for large particles, and very small
particles in micron range are less influenced by hydrodynamics.
apph
Relevance to In Vivo Conditions 
The unique result, namely, is independent of fluid velocity for the very small
particles, suggests that the highly variable GI fluid velocity varying with GI motility
apph
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phases may not impact on the of low micron range particles in in vivo.  The 
micronized powder of felodipine, with a median particle size of 8 m, may be an 
example of such a drug.  Felodipine is a poorly soluble, neutral and lipophilic drug, and 
its oral absorption that is indicated by AUC does not appear to be affected by the in vivo
hydrodynamics in dog studies.
apph
47,48  The independence of on GI motility, for small
particles such as jet-milled material, imply that the in vivo variability would be 
significantly reduced within subjects and between subjects.  Therefore, reducing particle 
size not only improves the dissolution rate and absorption fraction for poorly soluble 
drugs, but also potentially minimizes the in vivo variability. 
apph
However, it should be emphasized here that establishing in vitro dissolution
methodology reflecting in vivo scenario requires considerations in many aspects.  For
example, pH and surfactants are critical in selecting an appropriate dissolution medium.
Additionally important factors include the fluid velocity and device geometry, which 
combine to determine the dissolution hydrodynamics.  One disparity between dissolution 
testing and the in vivo situation is that the paddle speed remains unchanged during a 
given dissolution test.  By contrast, the GI tract regularly transitions through migrating
motility cycles and fasted or fed states.  Hence, the GI fluid velocity varies considerably
along various regions of small intestine,49-52 which can lead to large inter- and intra-
subject variations in in vivo .  To mimic the wide range of in vivo , it may be
more appropriate to vary the in vitro hydrodynamic conditions during a test e.g. paddle 
speed (Type II tester), dip rate (Type III) and flow rates (Type IV).  It is unrealistic to
assume that use of a single USP dissolution setting such as 50 rpm can reflect the 
complete hydrodynamics of a full GI motility cycle.  However, a single paddle speed
apph apph
49
might be used to represent one certain GI motility-fluid flow and particle size 
combination.
Revision of the test apparatus design to better reflect the geometry of the intestinal
tract and its flow patterns should be considered.  One particularly important aspect to 
consider is the representation of oscillating flow, corresponding to the segmental mixing
in the fed state, which is unique in its effects on in vivo .  Applying dimensional
principle, the in vivo is a function of: 
apph






, where Re  and  are 
defined as previously, and St is the Strouhal number describing oscillatory fluid. St





, where is vortex shedding, l is the characteristic 
length (hydraulic diameter), and 
f
0  is the linear velocity of GI fluid.
Potentially, a dimensionless analysis of the in vitro hydrodynamics and the in vivo




would be useful in improving accuracy 
of predicting in vivo dissolution and absorption of drug products, enhancing correlation 
between in vitro dissolution and in vivo response and developing in vitro bioequivalence 
methods.
Conclusions
The diffusional layer thickness was determined through fenofibrate powder 
dissolution testing in a USP apparatus II with various particle sizes and paddle speeds. 
The dependence of on drug particle size and dissolution hydrodynamics, reveals that 





occurs below and above a transitional size of 23.7 m, respectively.  Further, the result at 
50 rpm suggests that a diffusional  being linearly proportional to square root of 
particle diameter is an overall better functional form.  Further, dimensionless analysis 




 with particle within specific particle-
hydrodynamic regime.  However, the extrapolation of in vitro results to the in vivo
situation requires further investigation due to the in vivo hydrodynamics varying with 





Table 2.3.  Particle sizes and Re: comparison of fenofibrate powder dissolution in a USP 
dissolution apparatus II and previous studies using the function form of Eq 2.
System Particle diameter
range ( m)
Reynolds numbers of fluids 
aUSP dissolution apparatus II 2 – 106 0 <  < 5.8×10eR
4
Mass transfer from single 
particles and packed beds12-14
600 -1100 1 <  < 7×10eR
5
bMass transfer from a fixed 
solid sphere in fluid flow15
1270 20 <  < 10eR
3
cMass transfer of solid particles
suspended in agitated tanks17
15 - 600 325 <  < 1.08×10eR
5
dEstimate the k value of 
polydisperse solid particles18
Not defined.  Not defined in the paper.
Mass transfer of a single 
particle in creeping-flow22
Not defined. The correlation is
every good as of: 1<  < 10eR
3
Reasonable as of: 103<  < 10eR
4
a: The unit for rotational speed  is rpm, for particle size  is cm.d
b: Overall mass transfer for the fixed sphere.
c: The fluid velocity was estimated using slip velocity presented in Harriott’s paper.
d:  is the mass transfer coefficient and equals to k
apph
D .




















1: Equilibrate at -80.00 °C
2: Ramp 5.00 °C/min to 100.00 °C
3: End of method
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Figure 2.1a.  DSC thermograms of the jet-milled fenofibrate.
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1: Equilibrate at -80.00 °C
2: Ramp 5.00 °C/min to 100.00 °C
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Figure 2.3. Particle size distribution of fenofibrate powders. 
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Figure 2.5.  Dissolution profiles of various size fractions of fenofibrate powder at 50 rpm 
and 100 rpm.  (Error bars represent the standard deviation of a mean of three 
experiments.)
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h app  = 1.7057r
R2 = 0.9872
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Figure 2.6. Bifunctional analysis of the dependence of diffusional layer thickness  on 
particle sizes under different hydrodynamics in a USP dissolution apparatus II (n = 3).
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Figure 2.7. Dependence of  on square root of particle sizes under different 
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Figure 2.8.  Dimensionless analysis of the dependence of diffusional layer thickness
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CHAPTER III
SOLUBILIZATION AND DISSOLUTION OF INSOLUBLE WEAK ACID, 
KETOPROFEN: EFFECTS OF PH COMBINED WITH SURFACTANT 
Abstract
This study investigated the combined effect of pH and surfactant on the solubility and 
dissolution of ketoprofen (KP), a highly permeable and an ionizable and water-poorly 
soluble drug in gastrointestinal tract.  The equilibrium solubility of KP  was determined
in buffers at the pH range from 4.0 to 6.8 and sodium lauryl sulfate (SLS) concentrations 
from 0% to 2.0%.  Its intrinsic dissolution rate was measured in the same media using a 
rotating disk apparatus.  A simple additive model accounting for the free unionized KP
and ionized KP forms, and their corresponding micellar forms was employed to study 
the in-vitro solubility and dissolution behavior. Nonlinear regression analysis showed 
that the proposed model agreed well with the experimental data, with 96.0Rsq
( ) for the solubility study, and 0001.0P 0.98Rsq  ( 0001.0P ) for the intrinsic 
dissolution rate measurement.  The  and values are estimated as 4.76 ± 0.00 and 
0.253 ± 0.05 mg/mL, respectively, in good agreement with literature reports.  The 
micellar solubilization coefficient for the unionized is 757 ± 165 L/mol,





coefficients of various species: , and , are 7.68 × 10, , [ ]micelleKP KP KP micelleKP ][
-6,
1.54 × 10-6, 2.32 × 10-7, and 2.13 × 10-20 cm2/s, respectively.  The maximum
enhancement of solubilization is approximately 232-fold, while the maximum dissolution 
amplification is only 54-fold because of the smaller diffusivity of micellar species. The 
dramatic enhancement of in-vitro solubility/dissolution attributable to an increase of pH 
and presence of SLS mimics the in-vivo solubilization/dissolution behavior of KP along
the gastrointestinal tract, when the pH increases from 1-2 in the stomach to 5-6 in the 
duodenum. The results suggest that the KP dissolves very rapidly in small intestine, 
implying that its absorption will be predominantly controlled by gastric emptying, and 
only minimally limited by the subsequent dissolution processes. This behavior is very 
similar to BCS I drugs, thus KP may be considered for possible waivers of 
bioequivalence.
Introduction
The Biopharmaceutics Classification System (BCS) categorizes drugs into four 
classes according to their solubility and permeability 1.  BCS I compounds can be waived 
of the in-vivo bioequivalence study because of its high solubility and high permeability.
Whereas, the BCS II class of compounds exhibit high permeability and low solubility 
relative to the administered dose. Solubility, one of the key parameters in BCS, as well as 
dissolution rate are the most essential factors controlling the rate and extent of drug 
absorption.  The in-vivo drug solubilization and dissolution processes are complicated by 
a number of physiological processes and factors in the gastroenterological tract, such as 
gastrointestinal motility 2,3, pH, bile salts, buffer capacity, ionic strength, food intake and 
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viscosity 4.  Among them, pH and surfactant reflect the gastrointestinal pH change and 
the presence of bile salts.  They are also the major physiochemical determinants of drug 
dissolution.  Both surfactant and pH effects are important when considering ionizable 
drugs, particularly those with the pKa values in the gastrointestinal pH range.
The individual effect of pH and surfactants on the solubility and dissolution of
drugs has been studied previously.  As early as 1960’s, Olander proposed both the film
theory and the surface-renewal theory of simple mass transfer in conjunction with various 
equilibrium reactions 5.  Monney et al applied the film model to studying the pH effect on 
drug dissolution 6,7.  Other researchers studied the effect of surfactant on solubilization 
and dissolution of drugs.  For example, Rippie et al investigated the solubilization effect 
of polysorbate 80 on weakly acidic and basic drugs 8; and Elworthy et al analyzed the 
effect of four different nonionic surfactants on the dissolution of poorly soluble drug, 
griseofulvin 9.  During the late 1970’s and early 1980’s, research on the effects of pH 10,11
and surfactant 12,13 on drug solubilization and dissolution focused on disintegration and 
dissolution of traditional tablets.  Later, the dissolution theory was further advanced with 
the establishment of the convective diffusion model.  This model was first developed by 
McNamara and Amidon 14 and followed by others 15,16 to describe the effects of 
ionization at the solid-liquid surface and irreversible reaction of the dissolved species in 
the hydrodynamic boundary layer.  In the last decade, drug solubilization/dissolution 
research has evolved to the stage of investigating the pH or surfactant effects on 
controlled-release dosage forms 17 in polymeric matrix, studying their combination
effects with food uptake 18, and working with poorly water-soluble drugs 19,20.
However, the combined effects of pH and surfactants on the solubilization and 
dissolution of weak acid drugs has received little attention, especially in view of 
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reflecting an in-vivo change of pH and surfactant along the gastrointestinal tract using an 
in-vitro model.  The purpose of this paper is to investigate the effects of pH combined
with surfactant on the solubility and dissolution of BCS II water-poorly soluble weak 
acids in an in-vitro environment.  In this paper ketoprofen is selected as a model
compound for its desirable biopharmaceutical properties, including an approximate pKa 




Solubilization by pH combined with Surfactant – an Equilibrium Model
The equilibrium model, as shown in Scheme 1, was established by Jinno et al 21.  It 
is employed here to describe the effects of pH and surfactant on the equilibria of KP in 
aqueous solutions.  In the scheme, the pH effect is associated with an ionization 
equilibrium and the surfactant effect includes two solubilization equilibria.
The pH effect is described as an ionization process, shown as the following: 
KPKPa cHcK /])[(       (1)
where is hydrogen ion concentration, is the dissociation constant of ketoprofen, 
and and are the concentrations of unionized and ionized ketoprofen, 
respectively.  The surfactant effect exerts its micellar impact not only on the unionized 




micelleKPmKP ccck ][][ /))((*      (2)
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micelleKPmKP ccck ][][ /))((**     (3)
cmcccm surfactant       (4)
where k* and k** are the equilibrium constants for micellar solubilization of unionized 
drug and ionized drug, whereas and are the concentrations of 
unionized and ionized drugs in the micelle, and is the concentration of micellar
surfactant.  The value of is determined using eq 4, and the critical micelle
concentration (CMC) of sodium lauryl sulfate is taken from literature 
micelleKPc ][ micelleKPc ][
mc
mc
22,23 as 0.008 M 
that is equivalent to 0.25% (w/v).
Total Solubility 
The total solubility of a weak acid or a weak base in surfactant-containing buffers
was discussed previously in literature 8,24.  For ketoprofen, its total solubility  can 
be expressed as a sum of the solubility values of individual 
totalc
KP  relevant species:
micelleKPmicelleKPKPKPtotal ccccc ][][    (5) 












1[    (6) 
It is noticed that the value of , namely the intrinsic solubility of ketoprofen, is 
constant for all tested experiments due to the existence of excess amount of  in the
system.  Therefore, a dimensionless solubility number,  (equal to ), is 
introduced to illustrate the extent of solubilization power.
KPc
solidKP
SPc KPtotal cc /
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Furthermore, eq 6 can be transformed into eqs 7 and 8 that clearly reveal how 
changes according to the pH and surfactant, respectively.  Eq 7 consists of two 
components, each of which comprises both the free solute form and the micelle-
solubilized form, and respectively represents the solubility of unionized drug in the 





Kck am .  The solubility of the 
ionized drug rather than the unionized drug is the component influenced by the pH effect. 
For a given surfactant concentration , eq 7 suggests that the total solubility of KP 
increases reciprocally with concentration and thus exhibits a positive log-linear 
relationship with pH.  In addition, eq 7 also suggests that higher values of  would lead
to greater sensitivity of the total solubility relative to pH changes.  This is primarily due 









Kckcc amKPtotal .  For a given concentration or 
pH, eq 8 shows that would increase linearly with the micellar concentration .











Kkk a .  The value of the intercept is determined
by the pH of the solution.  In comparison, the slope is determined not only by the pH but 
also by the drug-micelle association constants.  For a weak acid drug, a higher value of 



























1(    (8) 
Total Dissolution 
The general equation describing one-dimensional mass transport in a fluid 25 is 
composed of the diffusive, convective, and reactive contributions and is shown as 
follows:
2 2/ / /i i i Z ic t D d c dz dc dz Ri    (9) 
where , and are the diffusion coefficient, the molar concentration, and the rate of 
reaction per volume of species i , is the fluid velocity, and 
iD ic iR
v t is the time.  Assuming an 
instantaneously irreversible reaction at the solid-liquid surface, mass transfer in the 
rotating disk system at steady state can be simplified to
2 2/ / /i i i Z ic t D d c dz dc dz 0     (10)
where is the axial velocity of fluid toward the disk. Levich solved the equation to 
derive the flux of the solute from the rotating disk as 
Zv
0
2/16/13/262.0 ii cvDJ       (11)
where is the flux, v is the kinematic viscosity, is the diffusivity of species i , is
the concentration of species i at the disk surface, and 
J
iD 0iC
is the angular velocity of the 
disk. Eq 11 is applicable for the micelle-facilitating dissolution of KP from a rotating 
disk and gives: 
)(62.0 0
3/22/16/1
iitotal cDvJ      (12)
where is the total flux of the drug, which is a sum flux of four KP related species 
and expressed as 
totalJ
72
micelleKPmicelleKPKPKPtotal JJJJJ ][][    (13) 
The dissolution rates of individual species are as follows: 
0
3/22/16/162.0 KPKPKP cDvJ      (14)
0










][ 62.0   (17) 
Substituting , , , and in eq 13 using eqs 14-17 gives the 
total flux:



































Assuming that the diffusion coefficients of all species are constant under the tested 
experimental conditions, the pH and surfactant effects on the total dissolution rate can be 
simplified and discussed as following.  First, the flux contributed from the unionized free 
drug is constant for all tested experiments due to the invariable values of  and 
.  Secondly in terms of the effect of pH on the total dissolution rate, eq 18 indicates 
that it exhibits only through ionized drug molecules, either in the free solute form or 
















KckDcv ammicelleKPKP  for 
the free solute and the micellar form, respectively.  Thirdly in terms of the surfactant 
effect on the total dissolution rate, eq 18 demonstrates that it exists in both the unionized 
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and ionized form, whereas the unionized form may contribute more significantly.  This 
premise is resulted mainly from some previous observations 21,26,27 that the micelle
association constant for the unionized form is much larger than that of the ionized form.
Materials and Data Analysis 
Ketoprofen (KP) and sodium lauryl sulfate (SLS, > 99% purity) were purchased 
from Sigma Chemical Company (St. Louis, MO).  HPLC grade acetonitrile was 
purchased from Fisher Scientific Company (Fair Lawn, NJ).  All other chemicals were of 
analytical grade from Sigma Chemical Company (St. Louis, MO).  Distilled, deionized 
and filtered water was prepared in house and used for all experiments. Model fitting and 
parameter estimations were performed with nonlinear regression analysis by Sigmaplot
8.0 (SPSS Inc., Chicago, IL).  The regression analysis for the dissolution data was 
weighted by reciprocal values of square of the standard deviation.
Media Preparation 
A series of McIlvaine buffers were prepared at pH 4.0, 4.6, 6.0 and 6.8 by mixing
appropriate volumes of 0.1M citric acid and 0.2 M disodium phosphate solutions.  SLS 
was dissolved with the buffers at the concentrations of 0.5, 1.0, and 2.0% w/v. All media
were deaerated by stirring under vacuum prior to use.
Solubility Determination 
An excess amount of ketoprofen powder (5-1000 mg) was shaken in screw-capped 
vials containing 5 mL of tested buffers at 37ºC in an orbital shaker water bath (LABLINE 
Instruments, Inc., Melrose Park, IL).  The final pH of the testing solutions were checked 
and adjusted to the original values by adding 0.5 M disodium phosphate solution.  At 
suitable time intervals, 1.0 mL of samples were collected and filtered through 0.45 mm
membrane, and then diluted with appropriate amount of buffers prior to the HPLC 
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analysis.  The equilibrium solubility of ketoprofen in various buffers was established as 
the difference between three consecutive measurements is within 1%.  The HPLC was 
equipped with a pump (Model 510, Waters Associates, Milford, MA) operated at 1 
mL/min, a sample processor (WISP Model 712, Waters Associates, Milford, MA), a 
variable wavelength UV detector (Spectroflow 783 Absorbance detector, Kratos 
analytical Instruments, Ramsy, NJ) set at 254 nm and connected to an integrator (HP 
3396 Series II, HP Company, Avondale, PA).  The mobile phase consisted of water (pH 
3.2): acetonitrile (35/65 v/v).  The analytical column used was a LiChroCART  column
(250 x 4 mm I.D.) packed with LiChroCART  100 RP-18, 5µm particle size (EM 
Science, Gibbstown,NJ) preceded by a LiChroCART  guard column (4 x 4 mm) of the 
same packing material.  The retention time of ketoprofen under these conditions was 
about 5 minutes.
Intrinsic Dissolution Measurements
The intrinsic dissolution rates of ketoprofen in various buffers were measured using 
rotating disk method.  Ketorpofen powder (150 mg) was compressed to form a circular 
compact, with a radius of 0.55 cm, in the rotating disk die at 1,000 lbs for 1 minute using 
a hydraulic laboratory press (Fred Carver, Inc., Summit, NJ).  The die containing the 
compact was mounted onto a Plexiglass shaft attached to an overhead synchronous motor
(Cole-Parmer Scientific, Niles, IL). The die was rotated at 50, 100, and 200 rpm, which 
was calibrated with a digital tachometer (Cole-Parmer Scientific, Niles, IL).  The single 
face of the compact was exposed to 150 mL of the dissolution media in a jacketed beaker 
maintained at 37 C  1 C through the circulating water heated with a water bath 
circulator (Isotemp Constant Temperature Circulator Model 8000, Fisher Scientific, 
Pittsburgh, PA).  The dissolution medium was continuously circulated through ultraviolet 
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(UV) spectrophotometer flow cells at 8 mL/min using a peristaltic pump (Masterflex, 
Cole-Parmer Instrument Co., Chicago, IL).  UV absorption at 258 nm was recorded at 
0.25-1 min intervals using a UV spectrophotometer (Perkin-Elmer Lambda 3B UV/VIS 
Spectrophotometer, Oak Brook, IL).  Dissolved amounts of ketoprofen was maintained at 
less than 10% of the solubility over the entire experiment ensuring sink condition.
Results and Discussion 
Total Solubility
The equilibrium solubility of ketoprofen in various buffers containing 0-2% (w/v) 
SLS is shown in Table 3.1.  Eq 6 was selected to fit the measured solubility values by 
nonlinear regression analysis.  Figure 3.2 illustrates the 3D mesh plot with the observed 
values as functions of pH and SLS concentrations ( 0001.0,96.0 PRsq ).  The 
, , , and values were estimated as 0.253 ± 0.05 mg/mL, 4.76 ± 0.00, 757 
± 165 L/mol, and 9.88 ± 6.70 L/mol, respectively.  The estimated  and  values 
agree well with the reported data 
KPc apK *k **k
KPc apK
28,29. The smaller value relative to  is 
suggestive that the micellar solubilization of ionized drug is fairly insignificant 
presumably as a result of the anionic nature of SLS.
**k *k
Using the estimated  number (i.e., 0.253 mg/mL), the corresponding 
solubilization power values were calculated based on eqs 7 and 8 are listed in Table 3.2.
The results indicate that the total solubility  increases positively with pH for any 
given SLS concentration, as expected.  In the absence of SLS, the maximal solubilization 
power is obtained at pH 6.8 with a value of 142.  In the presence of SLS, the combined




effect.  At pH 6.8 with 2.0% SLS, in particular, an exceptionally high solubilization 
power value of approximately 205 is observed.  This observation is consistent with eq 7.
As previously discussed, eq 7 expects an increased solubilization of both the unionized 





K , respectively.  In addition, the fractional solubility from the unionized 
drug and the corresponding micelles, or that from the ionized drug and its micelles, is pH 
dependant.  This is resulted from the interplay of pH and SLS on the ionizable drugs.  For 
instance, at pH << , the solubility contribution from the ionized drug and its micelles
is small relative to that of the unionized drug mainly because the value of  is much
smaller compared with the .  On the other hand, at pH >> , the solubility 
contribution from the ionized drug and the micelles becomes more significant.
Furthermore, it appears that KP solubility is more sensitive to pH change than to the SLS 
changes.  This is can be simply derived from Table 3.2 that pH could be enhance 





The solubility results also indicated that the total solubility increased proportionally 
with SLS concentration for any given pH value, as showed in Table 3.2 that all the 
corresponding linear regression analysis had Rsq > 0.98.  This observation is indeed 










kk a .  Furthermore, eq 8 also suggests that at higher pH the total 





Kk a becomes greater.  This contribution, however, is quite limited
on account of the very small value of .**k
Intrinsic Dissolution Rate 
A typical intrinsic dissolution rate as a function of the square root of the rotational 
speed is illustrated in Figure 3.3.  The intrinsic dissolution rates were normalized to 
with the unit of by multiplying the volume of
media (150 mL) divided by the surface area of the compact (0.95 cm
2/1/J 2/12/124 ///10 radscmmg
2) using linear 
regression assuming zero intercept.  Similarly, the dissolution flux increases with pH and 
addition of SLS.  The dissolution flux is found to be linear with SLS concentration at all 
pH values (Rsq: 0.93-0.99).  The intrinsic dissolution rates of ketoprofen in various 
buffers containing 0-2% (w/v) SLS are presented in Table 3.3.  Using the estimated
values of , , , and obtained from the solubility study, the measured
intrinsic dissolution rate data were fitted to eq 18 by nonlinear regression analysis. 
Figure 3.4 illustrates the dissolution rate result ( ) of the fitted surface plot with 
the experimental data as functions of pH and SLS concentrations 
( ).  The estimated diffusivity values for species 
, and are 7.68 × 10
KPc apK *k **k
2/1/J
0.98, 0.0001Rsq P
, , [ ]micelleKP KP KP micelleKP ][
-6, 1.54 × 10-6, 2.32 × 10-7, and 2.13 × 
10-20 cm2/s, respectively.  It is apparent that the diffusivity value of  is trivial.
Thus, the flux contribution from the micellar form is negligible.  Then, eq 18 can be 
simplified as the following:
micelleKP ][
1/ 6 1/ 2 2 / 3 2 /3 2 /3
0 [0.62 ( * )[ ] micelle
a
total KP KP KP mKP
KJ v c D D D k
H ]
c   (19) 
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In eq 19, it becomes evident that the flux is composed of three fractions.  One fraction is 
the constant flux from the unionized drug KP .  The second fraction is the pH-influenced 
flux from the ionized drug KP .  And the third fraction is the surfactant-controlled flux 
from the unionized micelles .  As a result, the most significant dissolution 
enhancement should be achieved at maximum pH and SLS concentration.  In fact, the 
maximal dissolution enhancement is about 50-fold at pH 6.8 with 2.0% SLS.
micelleKP][
Interestingly, the effect of pH and surfactant on the intrinsic dissolution rate are 
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KP  contribution would
be small.  Accordingly, the surfactant effect would appear to be more significant.  On the 





D aKP becomes more substantial compared with .  Hence, the 
effect of pH would be more dominant in the KP dissolution.  This phenomenon was 
observed in the study as shown in Table 3.3.  In particular, at pH 4.0, the enhancement of 
flux with 2.0% SLS is about 42.5-fold, whereas at pH 6.8, the corresponding flux 




The overall dissolution amplification is moderate in contrast to the solubility 
enhancement owing to the much smaller diffusivity of micellar species.  In fact, the 
diffusivity of the micellar is in essence zero.  Additionally, the value
is about 33 times lower than the value presumably by reason of a much higher 
micelleKP ][ micelleKPD ][
KPD
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molecular weight of the micelle form.  This ratio is much higher than the ratio of 9.0 
observed with the carbamazepine-SLS system 30 and the 1.7 observed with the 
piroxicam-SLS system 21.  The rather low diffusivity of in turn may be on 
account of an inherent higher micellar solubilization equilibrium coefficient (k*) relative 
to the reported values of approximate 300 L/mol for carbamazepine
micelleKP ][
30 and 348 mol/L for 
piroxicam 21.  The absolute diffusivity values of free KP  and the  forms, however,
are within the same numerical range as those of carbamazepine
KP
30, piroxicam 21 and 
benzoic acid 31.
Regulatory significance: potential waiver of in vivo bioequivalence 
Recently, a Guidance for Industry was published in the Federal Register that 
proposed a waiver of in vivo bioavailability and bioequivalence studies for immediate
release solid oral dosage forms containing Class I active moieties/active ingredients of 
the biopharmaceutics classification system 32.  This guidance pertains to highly water-
soluble and highly permeable drugs that satisfy the following major conditions: 
a. the highest dose strength is soluble in 250 mL of water or less over the pH range 1-
7.5;
b. the extent of absorption in humans is determined to be 90% or more of an 
administered dose based on mass balance or compared to an intravenous reference 
dose;
c. 85% or more of the labeled amount of drug substance dissolves within 30 minutes
using USP apparatus I at 100 rpm or apparatus II at 50 rpm in a volume of 900 mL or 
less of the following media;
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1) acidic media such as 0.1 N HCl or simulated gastric fluid USP without enzymes; 2) a 
pH 4.5 buffer; and 3) a pH 6.8 buffer or simulated intestinal fluid USP without 
enzymes.
Class II drugs in the biopharmaceutics classification system possess low water 
solubility but are highly permeable.  Thus, these drugs would not satisfy all the Class I 
waiver requirements, in particular with the solubility and dissolution requirements.
However, Class II weakly acidic drugs with pKa in GI physiological range such as 
ketoprofen that may be completely ionized and thus highly soluble and rapidly dissolving 
in an intestinal milieu with an average pH of ~6.5, may be considered for the possible 
waivers of in vivo bioequivalence.
“Highly soluble” requirement 
Ketoprofen, like many other drugs, is mainly absorbed in the small intestinal region 
where an average pH of ~6.5 and containing total concentrations of bile salts and lecithin 
around 7 mM in the fasted state, or a pH of around 5-6 and a total bile salts and lecithin 
concentration of about 19 mM in the fed state 33-35.  As a carboxylic acid drug, it has been 
shown previously that increase of pH would enhance its solubility and consequently the 
dissolution rate, particularly at pH > pKa of the acid.  In addition, the bile salts are 
present in the small intestine.  Previous studies have demonstrated that bile salts improve
the in-vivo solubilization of many drugs.  Thus, their dissolution and absorption are 
enhanced accordingly.  This seems to be working with ketoprofen, as shown by the 
present study that SLS could serve as a bile salt improving its solubility and intrinsic 
dissolution.  As ketoprofen is taken orally, it would have minimal solubility/dissolution 
in the acidic stomach in consequence of the local low pH (1-2) environment.
Immediately after the drug is emptied into the upper small intestine, the 
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solubility/dissolution of ketoprofen would increase very quickly.  This is mainly due to 
two factors: the dramatic increase of pH and the presence of bile salts in small intestine. 
From the model in the present paper, KP would have the solubility of at least 0.7 mg/mL
at pH 5-6, even in the absence of any bile salts or surfactants. Consider an example of KP 
product with the maximum dose of 75 mg (Orudis , Wyeth-Ayerst Pharmaceuticals,
PA), the required dissolving volume for complete solubilization of KP would be less than 
110 mL. This volume is much smaller than the 250 mL dissolving volume, which is 
currently used by FDA 32 for defining “highly soluble” drugs to classify a BCS I 
compound.  Therefore, results in this paper suggest that KP can be defined as “highly 
soluble” drug at pH > 5-6.  Nonetheless, this “highly soluble” definition does not hold 
true over the entire pH 1.2-7.4 range, in particular for the low pH end.  With the 
consideration of high permeability of KP, it leads to support the hypothesis that the 
absorption behavior of KP could exhibit very similarly to that of BCS I compound in the 
local absorption region in the intestine.
“Rapidly dissolving” requirement 
In addition to the drug, it is of importance to consider the drug products that are 
formulated and manufactured in rapidly dissolving solid immediate release dosage forms.
For any KP immediate release products that dissolve very rapidly, the absorption kinetics 
from GI tract would be governed by the gastric emptying, rather than by the dissolution 
rate.  Therefore, the absorption rate will be essentially controlled by the gastric emptying
rate and no correlation with the solubility or dissolution rate is expected.  Thus, 
appropriate in vitro dissolution testing procedures may be established specifically for 
BCS II acidic drugs in the future for the assurance of a waiver of in vivo bioequivalence.
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Conclusions
In conclusion, we suggest KP, which possesses highly permeability, and is a weakly 
acidic drug with pKa in GI physiological range and thus exhibits pH enhanced solubility 
and dissolution rate in the absorption region, as a candidate for waivers of in vivo
bioequivalence.  The significance of the present study may be applicable to other weakly 
acidic drugs with high permeability.  For these drugs, their solubility measurement may
be conducted around pH 5-6 with appropriate SLS and their dissolution testing under 
aforementioned conditions for KP, which represents more biopharmaceutically and 
physiologically relevant pH.  Interestingly, it has been advocated by other researchers 
that the current FDA definition of “high solubility” may be too restrict for 15 acidic 
drugs 36, including ibuprofen, piroxicam, naproxen and indomethacin.  These drugs are 
all weak acids exhibiting pKa values ranging from 4.2-5.3 and log P (octanol-water) 
values between 1 (ketoprofen) to 3.8 (indomethacin) 29.  An example of a weak acid 
NSAID that does not conform to this general trend is mefenamic acid.  It has been 
reported that the enhancement of mefenamic acid upon ionization, though substantial is 
not sufficient to satisfy dose volume requirement 37.  Hence, the absorption and 
bioavailability of mefenamic acid would be dissolution rate-limited.  A more general 
conclusion, therefore, for Class II weakly acidic drugs should stipulate that a) the drug 
should be highly permeable (> 90% absorption in humans; Peff ~ 2.5 103 cm/s;
absorption half-time ~ 1h); b) that it be substantially ionized at a pH of 6.5 and/or c) that 
it satisfy high solubility requirements at pH 6.5.  Under these circumstances, such Class 
II drugs would be essentially similar to Class I drugs and could be considered for waivers 
of in vivo bioequivalence testing.
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In summary, the solubility and intrinsic dissolution rate behavior of ketoprofen is 
well characterized by the additive model described in this paper.  Even though the in-vivo
case is complicated with gastric emptying and other physiological factors, the 
solubility/dissolution enhancement due to an increase of pH and the presence of SLS 
could reflect the in-vivo solubility/dissolution behavior along the gastrointestinal tract. 
The study supports the possibility for ketoprofen and other BCSII weak acids that 
dissolve rapidly and completely in small intestine, to be waived of in vivo
bioequivalence.
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Table 3.1. Equilibrium solubility (mg/mL  S.D.) of ketoprofen at various pH and SLS 
concentrations.
SLS concentration (%, w/v) 
pH 0.0 % 0.5 % 1.0 % 2.0 % 
4.0 0.28 ± 0.01 2.23 ± 0.03 4.70 ± 0.04 13.09 ± 0.04
4.6 0.49 ± 0.00 2.62 ± 0.02 5.61 ± 0.11 14.90 ± 0.50
6.0 3.68 ± 0.13 6.11 ± 0.12 9.26 ± 0.13 19.73 ± 0.46
6.8 40.76 ± 0.01 44.25 ± 0.00 49.63 ± 0.01 58.80 ± 0.01
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Table 3.2. Solubilization power (CSN) of various pH and SLS concentrations on 
Ketoprofen.
SLS concentration (%, w/v) 
pH 0.0 % 0.5 % 1.0 % 2.0 % Slope1 Rsq1
4.0 1.24 8.82 18.58 51.76 822.84 0.990
4.6 2.17 10.36 22.18 58.92 927.04 0.992
6.0 16.33 24.16 36.62 78.02 1013.45 0.987
6.8 161.17 174.97 196.24 232.50 1151.86 0.996
1: indicate the linear regression of Ctotal vs SLS for a given pH.
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Table 3.3. The intrinsic dissolution rate ( ×  of 
ketoprofen at various pH and SLS concentrations. 
,/ 2/1J 4 2 1/ 2 1/ 210 / / / . .)mg cm s rad S D
SLS concentration (%, w/v) 
pH 0.0 % 0.5 % 1.0 % 2.0 % 
4.0 1.68 ± 0.03 4.15 ± 0.03 6.05 ± 0.09 9.20 ± 0.16 
4.6 3.05 ± 0.04 6.18 ± 0.05 8.30 ± 0.16 11.35 ± 0.11
6.0 14.61 ± 0.15 17.38 ± 0.09 20.32 ± 0.13 21.90 ± 0.32

















Scheme 3.1. Equilibrium model of ketoprofen in surfactant containing buffers. KPsolid:
solid-state drug molecules; KP: dissolved and unionized free drug; KP-: free ionized 



































































































Figure 3.4. The intrinsic dissolution rate as function of pH and SLS.
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A COMPARISON OF PHOSPHATE AND BICARBONATE BUFFERS:
RELEVANCE TO IN VIVO DISSOLUTION
Abstract
To evaluate the difference between the pharmaceutical phospha te buffers and the 
gastrointestinal bicarbonates in dissolution of ketoprofen and indomethacin, to illustrate 
the dependence of buffer differential on biopharmaceutical properties of BCS II weak 
acids, and to recommend phosphate buffers equivalent to bicarbonates. The intrinsic
dissolution rates of, ketoprofen and indomethacin, were experimentally measured using 
rotating disk method at 37°C in USP SIF/FaSSIF and various concentrations of
bicarbonates, and also theoretically forecasted using a reaction plane model that was 
improved in this work. Experimental results shows that the intrinsic dissolution rates of 
ketoprofen and indomethacin, in USP and FaSSIF phosphate buffers are 1.5-3.0 folds of
that in the 15 mM bicarbonates, which is in good agreement with the theoretical analysis.
Theoretical analysis demonstrates that the buffer differential is largely dependant on the 
drug pKa and solubility, and weakly dependant on the drug diffusivity.  Further, in
accordance with the drug pK, solubility and diffusivity, simple phosphate surrogate was
proposed to match an average bicarbonate value (15 mM) at the upper gastrointestinal 
region.  Specifically, surrogate phosphate buffer of 13-15 mM and 3-4 mM were
recommended for ketoprofen and indomethacin, respectively, whose dissolution
demonstrated high satisfaction with respective 85% and 104% equivalence in the 15 mM
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bicarbonate buffer. This work highlights the substantial difference between
pharmaceutical phosphates and physiological bicarbonates in determining the drug
intrinsic dissolution rates of BCS II weak acids, such as ketoprofen and indomethacin.
Based on both theoretical analysis and experimental confirmation, surrogate phosphates 
were recommended in order to closely reflect the in vivo dissolution of ketoprofen and 
indomethacin in gastrointestinal bicarbonates.
Introduction
Drug dissolution is the prerequisite to drug absorption and the subsequent clinical
response for almost all drugs administered orally. For Biopharmaceutics Classification 
System (BCS) Class II drugs with high permeability and low solubility, the ir drug 
absorption is rate limited by in vivo drug dissolution.  Thus, a correlation between an in
vitro dissolution and in vivo performance is expected if the in vitro dissolution rate is 
similar to the in vivo dissolution rate 1.  To achieve this objective, the in vitro dissolution 
testing should be reflective of the in vivo situation. However, various components of the 
GI tract, such as transit time, hydrodynamics and fluid contents, present a complex nature 
of in vivo gastrointestinal fluids in upper small intestine 2-7. Particularly, the dissolution
media whose contents should mimic GI fluids, including pH, buffer species and
concentration, bile salts, electrolytes, enzymes and a wide range of lipids, are important.
In the past, developing biorelevant in vitro dissolution medium has attracted numerous 
interests 4,8-12, resulting in several widely used in vitro dissolution media.  For example, 
the most dominant media include the USP simulated intestinal fluids (SIFs) 13 and fasted-
state simulated small intestine fluids (FaSSIF) 4,8,14, as shown in Table 4.1.  However, 
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their focus has been on simulating the gastrointestinal (GI) pH and bile salts.  Further, the 
buffer species in these two media is phosphate. One seemingly very obvious choice,
however, the GI buffer species, namely the bicarbonates, has been overlooked.
The principle physiological buffer along the human GI tract is not phosphate, rather
the bicarbonate. Gastroduodenal bicarbonate has long been known as the main buffer 
system maintaining a pH gradient along the gastrointestinal lumen 15. Bicarbonate is a 
ubiquitous component in human secreted fluids and is actively secreted by the pancreas 
to neutralize gastric secretion in the GI lumen.  It has also been shown that epithelial cells 
of the duodenum secrete bicarbonate, which is an important mechanism to protect the 
duodenal epithelium against acid discharged from stomach 16-21. Bicarbonate
concentrations in human GI fluids have been reported to be within a dynamic range,
depending on the fasted and fed states as well as local regions along the GI tract 17,19,22,23.
For example, as early as in 1935, the bicarbonate concentration was measured directly 
from the fasted human duodenum using titration method, and the values were reported in
the range of 4-21 mM 24,25, with an average of 15 mM 23. In 2001, Repishti et al.
measured the pH and 
2COP in human duodenum, and used the Henderson-Hasselbalch
equation to calculate that the bicarbonate HCO3- in fasted-state duodenum has a mean
value of 6.7 ± 0.34 mM at pH 7.22 26. Person et al. 5 showed that the mean value of the 
buffer capacity of human jejunum at fasted state is 2.4-2.8 mmolL-1pH-1, which
corresponds to 18.1 mM of bicarbonate concentration at pH 7.5 assuming that the buffer 
capacity is solely attributed by the buffer species.  Recently, Kalantizi et al.6 reported the 
range of buffer capacity for distal duodenum of fasted human, which is equivalent to 4.35 
– 21.6 mM of HCO3- at pH 6.2. 
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Bicarbonate is the prevailing buffer in human gastrointestinal GI tract, however, it has 
rarely been used 27 mainly due to the inconvenience of maintaining a constant pH and 
HCO3- concentration in the dissolution medium through continuous CO2 gas purging.
Almost all pharmaceutical dissolution studies rather use phosphate or acetate buffers, 
subsequently creating a disconnection with the buffer species between the in vitro and the
physiological GI in vivo situation. This disconnect should be closely evaluated, because,
not only buffer concentration but also buffer species can significantly impact dissolution 
rates of ionizable drugs, even if the pH of buffers is held constant 28-30.  It was shown that 
the intrinsic dissolution rates of naproxen increase with the escalation of buffer
concentration, which was demonstrated consistently in three buffers including phosphate, 
citrate and acetate 30. More interestingly, the work also showed that naproxen
demonstrated a decreased dissolution rate in the following buffer species: phosphate >
citrate > acetate, despite all the buffers were maintained at the same buffer concentration 
and same pH value 30. Therefore, it is important to compare the bicarbonate buffer with 
the commonly used USP SIF/FaSSIF phosphate buffers, in the perspective of
investigating their impact on dissolution rates of BCS II acidic drugs. This work is to 
focus on investigating the impact of GI buffer species and concentration on the
dissolution of poorly soluble and ionizable acidic drugs.
Using model BCS II weak acids, such as ketoprofen and indomethacin, we not only 
demonstrated the dissolution difference between phosphates and bicarbonates
experimentally, but also provided a mechanistic understanding of the buffer differential
theoretically. In doing so, we illustrated the dependence of buffer differential on
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biopharmaceutical properties of drugs, thus ultimately recommending simple phosphate
buffer surrogate to be equivalent to in vivo bicarbonates.
Theoretical Section
Reaction plane model
The reaction plane model was initially developed for describing chemical reactions
on a rotating disk 31, and it was extended to the pharmaceutical situations by Amidon et 
al. 30,32.  In the current paper, the reaction plane model was further improved to better 
predict the drug flux.
The general equation describing one-dimensional mass transport in a fluid 33 is 
composed of the diffusive, convective, and reactive contributions and is shown as the
following:
2 2/ / /
i i i Z i ic t D d c dz dc dz Rυ∂ ∂ = − + (1)
where iD , ic and iR are the diffusion coefficient, the molar concentration, and the rate 
of reaction per volume of species i  ( 3/mol cm s⋅ ), ν is the fluid velocity ( 2 /cm s ), and 
t  is the time (s). The overall mass transport includes the acid-base reactions and 
convective diffusion, which is fast and slow process, respectively. The continuity Eq 1 
can then be simplified by recognizing that slow processes control the overall mass 
transport.
Assuming instantaneous reactions at the solid- liquid surface, mass transport in a
rotating disk system at steady state is simplified as:
2 2/ / / 0i i i Z ic t D d c dz dc dzυ∂ ∂ = − = (2)
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Where zv is the axial velocity of the fluid toward the disk.  Litt and Serad 
31 have shown 
that Eq 2 can be scaled by introducing the dimensionless distance variable, n, for the 
axial distance z , as: 




−= Ω = =
0( ) ( )/( )in in ib i ibC n c c c c= − − (3)
1/2( ) /( )zV n υ ν= Ω
/i iSc Dν=
Where Ω is the angular velocity of the disk (rad/s), ν is the kinematic viscosity of the 
fluids (), inc is the molar concentration of species at distance n , inC is the dimensionless 
concentration of species i at position n, zv is the axial velocity of the fluid as reported by 
Riddiford 34 1/2 2 3[ ( ) (0.510 0.333 ....)]n nν− Ω − + , ( )V n is the dimensionless velocity of the 
liquid, and iSc is the dimensionless Schmidt number of species i .
2 2/ / 0i i id C dn VSc d C dn− = (4)
Levich has shown that the molar flux of acid from the disk surface is: 
0
1/2 1/3( / ) ( ) /1.613HA HA HA HAN D C Scν= Ω  and (5)
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After identifying various chemical reactions at the reaction plane, a set of mass balance
equations accounting for all reacting species were established.  When the flux of one 
species changes due to a chemical reaction at the reaction plane, it must be reflected by
the flux of the corresponding reactants or products as defined in the aforementioned 
reactions (Eq 6). Therefore at steady state, the following flux condition must hold at the 
solid- liquid interface: 
HA HBH OH A BN N N N N N+ − − −+ + = + + (7)
where +HN , HAN , HBN , −OHN , −AN  and −BN individually denote the molar flux of ,H
+
,HA ,HB ,OH − A−  and B− . It should be noticed that the flux of species of A−  and B−
have different signs because they are supplied from opposite directions, i.e., from the
solid surface or from the medium bulk to the reaction plane, respectively. Thus, the
electrical neutrality is maintained in Eq 7.







































the flux condition was rewritten explicitly in the following system equation (eq 8):
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where HBCT  is the total molar buffer concentration, ,0BC −  is the molar concentration of 
the basic component at the solid- liquid interface, HAaK  and 
HB
aK  are the ionization
constant of the drug and buffer, respectively.  The only unknown variables in system 
equation 8 are 
,0H
C +  and ,0BC − , which is readily solvable if the bulk pH, ionization
constants of the acidic drug and the buffer, the total buffer concentration, the intrinsic
solubility of the drug, and the diffusion coefficients of all species are available.  Once 
,0H













where totalN  is the total drug flux at a specific pH and rotating speed, which includes the 
flux from both species HA  and A− ; 0N is the drug flux at the same rotating speed, but 
dominant ly from species HA  when the ionization or reaction of HA  is negligible at low 




, rather than the absolute total drug flux at 
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specific condition, made the buffer comparison straightforward, because of employing 
the 0N  as the common standard.
Film model
The film model was derived originally in 1960’s 35 and applied to drug dissolution 
by Stella et al 28,36. It is assumed in the film model that the dissolution of drug ( HA ) into 
the aqueous media occurs through a diffusion layer-controlled process 28,29,36.  This 
diffusion layer is calculated according to the Levich rotating-disk model, which is based 
on the diffusivity of the drug ( HAD ) regardless of the presence of other species. Within
this boundary layer, all concentration gradients of the reactants and products exist as a 
result of diffusion and instantaneous reactions between the dissolving drug, the buffers,
hydroxyl ion and water.  Unlike the reaction plane model, all reactions are reversible and 
homogenous, and they are concurrent with diffusion throughout the boundary layer. The
final working equation was derived and detailed by Mooney et al. 28. The only unknown 
variable in film model is
,0H
C + , i.e., the H +  concentration at the solid- liquid interface, 
which is solvable by the Newton iterative method using Mathematica 5.1 (Wolfarm 
Research, Inc., Champaign, IL). Once
,0H
C +  is solved, the relative flux increase can be 
calculated using Eq 9.
Table 4.2 lists all the known parameters that were used in the reaction plane and 
film models, including the pKa values of model drugs and buffers, diffusivity values of
all species, and the solubility of the model drugs. In both models, only the predominant 
ionization of phosphate or bicarbonate,  under the working pH range of 6.5-6.8, was
considered because other ionization is negligible.  Specifically, for the phosphate buffer, 
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only the ,2apK of H2PO4
- was utilized; and for the bicarbonate, the ,1apK of H2CO3 was
considered.
Experimental Section 
Materials and Dissolution Media Preparation
Ketoprofen, indomethacin (> 99% purity), carbonic anhydrase, and all other
chemicals were of analytical grade and were purchased from Sigma (St. Louis, MO).
Distilled, deionized and filtered water was prepared in house and used for all
experiments.  Dried and compressed 100% CO2 was purchased from LifeGas (Ann
Arbor, MI).  All 3-D plots were generated using Sigmaplot 10.0 (SPSS Inc., Chicago, 
IL).
The USP SIF pH 6.8, 50 mM phosphate buffer without pancreatin 13 and fasted-
state simulated intestinal fluid (FaSSIF, 29 mM pH 6.5 phosphate buffer) without bile 
salts 4 were prepared following standard procedures. Sodium phosphate was used instead 
of potassium phosphate because the principle cationic species in fasted small intestine is 
sodium 2,37,38.  Previous study conducted by Reppas et al. 4 has demonstrated that 
substituting sodium for potassium in standard USP and International Pharmacopeia buffer 
systems has no practical effects on the dissolution process of weak acids. The 15 mM
bicarbonate buffer was established by initially preparing a 15 mM of sodium carbonate 
solution, and then the solution was continuously purged with CO2 (g) until pH was
reduced to 6.8 or 6.5. To ensure the bicarbonate buffer was equilibrating, both the pH 
and the total 2 3 3/H CO HCO
− (aq) content in the bicarbonate buffer was monitored.  The 
pH was continuously monitored with a standard pH meter and electrode (PHI™40,
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Beckman Coulter, Inc., Fullerton, CA), and the 2 3 3/H CO HCO
−  (aq) content was checked 
periodically using methods described previously 39-41 with a standard CO2 assay kit 
purchased from Sigma.  After the CO2 (aq) and the pH of the bicarbonate buffer reach an
equilibrium, which takes 30-40 minutes at 37°C, only pH is followed through the 
intrinsic dissolution testing.  To maintain a steady CO2 (aq) concentration and pH in the 
bicarbonate buffer at 37°C, a continuous CO2 (g) purge with a flow rate ~50 mL/min was
generally required. Prior to dissolution testing, all buffers were adjusted to be isotonic to
normal saline with NaCl. 
Intrinsic Dissolution Measurement
The intrinsic dissolution rates of ketoprofen and indomethacin in various buffers 
were measured using a rotating disk system.  Ketoprofen and indomethacin powder of 
150 mg was compressed under 2000 LBs and 5000 LBs, respectively, for 60 seconds to
form a circular compact with a radius of 0.45 cm using a hydraulic laboratory press (Fred 
Carver, Inc., Summit, NJ).  The die containing the compact was mounted onto a
Plexiglass shaft attached to an overhead synchronous motor (Cole-Parmer Scientific, 
Niles, IL). The die was rotated at 100 rpm, which was calibrated with a digital
tachometer (Cole-Parmer Scientific, Niles, IL).  The single face of the compact was 
exposed to 150 mL of the dissolution media in a jacketed beaker maintained at 37 ± 1°C
through the circulating water heated with a water bath circulator (Isotemp Constant 
Temperature Circulator Model 8000, Fisher Scientific, Pittsburgh, PA). At pre-
determined time points, 1.0 mL of dissolution sample was withdrawn and same amount 
of blank dissolution medium was refilled.  The ketoprofen and indomethacin
concentration in the dissolution media samples were measured using UV absorption at 
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258 nm and 265 nm, respectively, using a UV spectrophotometer (Beckman Coulter DU
650, Fullerton, CA). To ensure sink conditions, the concentrations  of ketoprofen or
indomethacin in the dissolution media were maintained less than 10% of their solubility 
for the entire experiment.  Dissolution flux (mass/time/area) of ketoprofen and
indomethacin were calculated as the multiplication of the slope of the concentration vs. 
time plot, volume of dissolution medium (150 mL), and area of the exposed disk 
(0.63585 cm2).  Individual dissolution experiments typically were carried out from 10 
minutes for ketoprofen and up to several hours for indomethacin.
For comparative purposes, dissolution flux of ketoprofen and indomethacin in the 
following isotonic media were determined: pH 6.8 USP SIF 50 mM phosphate buffer 
without pancreatin, pH 6.5 FaSSIF containing 29 mM phosphate buffer without sodium 
taurocholate or lecithin, and pH 6.5 various concentrations of bicarbonate buffers that 
covers a normal range of bicarbonate concentrations along the fasted human duodenum.
Buffers without any enzymes or bile salts were used to distinctively reveal the effects of 
buffer species. The final pH values of the dissolution media using phosphates were 
checked at the end of the dissolution experiments to assure that a constant pH has 
maintained throughout the dissolution testing.
Results
Dissolution of Ketoprofen and Indomethacin in Phosphate and Bicarbonate 
Buffers
The aim was to evaluate the dissolution difference of ketoprofen and indomethacin
in bicarbonates and  in the commonly used phosphate buffers. Table 4.3 lists the intrinsic
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dissolution rates of ketoprofen in two phosphates (USP and FaSSIF), and three
bicarbonate buffers with concentrations of 5, 15 and 20 mM, and Table 4.4 lists the flux 
ratio of indomethacin in phosphates versus in bicarbonates with concentrations of ranging 
6.4 – 25.8 mM.  As expected, the higher concentration of bicarbonate, the faster drug flux 
of indomethacin or ketoprofen to exhibit in the dissolution media.  This is because a 
greater driving force for the reaction between the weakly acidic drug and species 3HCO
− ,
as shown in Eq 10, exists with the presence of higher bicarbonate concentration.
3 2 3( )HA HCO A H CO aq
− −+ +  (10)
More importantly, the intrinsic dissolution rates in the USP SIF buffer and in the FaSSIF 
are higher than in all bicarbonate buffers.  For example, the respective dissolution rate of
ketoprofen in the USP SIF and FaSSIF is at least 200% and 50% faster than that in the 15
mM bicarbonate, an average value in fasted duodenum. Again, the intrinsic dissolution 
rate of indomethacin in phosphate buffer is higher, showing about 30 - 150% of flux 
increase compared with that in various concentrations of bicarbonate buffers.
In Tables 4.3 and 4.4, the main differences between the phosphates and
bicarbonates exhibit in pH (6.8 versus 6.5), buffer concentration and buffer species,
which all could contribute to the observed dissolution rate difference. To distinctively
reveal the effects of buffer species, intrinsic dissolution rates of ketoprofen were
measured in phosphate and bicarbonate with the same pH, i.e., 6.8, and the same buffer
concentration, i.e., 50 mM. The results in Table 4.5 showed the ketoprofen flux in this
phosphate was still 2-fold of that in the bicarbonate.  This experimental result supports
the hypothesis that even if at the same pH and the same buffer concentration, in
dissolution of ketoprofen, phosphate and bicarbonates are inherently distinctive from 
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each other. The distinction lie in the natural differences between phosphate and 
bicarbonate, namely, the pKa and the diffusion coefficient.
First of all, the pKa plays an important role in the driving force for the reaction
between the acidic drug and the basic buffer species.  At the solid- liquid interface, the 








k KHA B HB A K
k K
− −+ + = =  (11)
Eq 11 clearly indicates that a basic buffer with a higher pKa value translates into a
smaller HBaK , which yields a larger equilibrium constant K for the reaction. Consistent
with the experimental results, at 37°C phosphate buffer with an effective pKa of 6.533 
provides greater driving force for the acidic drug–buffer reaction than that of bicarbonate 
with a pKa of 6.31 (shown in Table 4.2), thus leading to faster dissolution rate for 
ketoprofen and indomethacin.
Secondly, the pKa difference in these two buffer species also results in different 
buffer capacity at the solid-liquid interface. For a system the same pH and the same
buffer concentration, phosphate buffer has about 23% higher buffer capacity relative to 















where β  is the buffer capacity. In general, the 
,0H
C + concentration at the solid- liquid
interface is lower than that in the bulk due to the ionization of acidic drug molecule.
Within the boundary layer or at the solid- liquid interface, the buffer capacity is controlled 
not only by the extent of acidic drug disassociation but also the buffer capacity. The
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higher buffer capacity of phosphate maintains the pH at the solid- liquid interface lower
than, but closer, to the basic environment of the bulk, in relative to the bicarbonate 
system. Thus, a greater extent ionization of acidic drugs and the subsequent increase of 
drug dissolution in the phosphates are present.
Thirdly, the diffusion coefficient of buffer species may also have an indirect impact 
on drug dissolution rates through diffusional layer thickness.  The Levich equation 42
indicates that the diffusional layer thickness 1/3 1/6 1 /21.612h D υ ϖ −= is accounted for one 
species, generally the drug molecule.  In reality, there are a number of species involved in 
drug dissolution using the rotating disk.  Therefore, it may be logical to consider the
boundary layer thickness is an average  value composed of all of the species involved in 
the dissolution. Thus, the species include not only the drug molecules but also the
conjugate buffers HB and B− , and OH − and H + .  It is apparent that a smaller diffusion
coefficient D  would produce a thinner boundary layer thickness, which implies less 
resistant during mass transport.  Specifically, the diffusivity for 22 4 4/H PO HPO
− −  is 
11.5×10-6cm2/s, which implies a thinner diffusional layer thickness and a subsequent
faster drug flux, in relative to 2 3H CO  and 3HCO
−  with respective diffusivity values of 
12.3×10-6cm2/s and 19.5×10-6 cm2/s.
The relative drug flux increase of ketoprofen and indomethacin was forecasted 
using the reaction plane and film models, which was summarized in Tables 4.3 and 4.4.
For ketoprofen, the reaction plane model excellently predicts its dissolution flux increase 
in phosphate buffer.  For example, the reaction plane model predicts the relative drug flux 
increase in USP SIF buffer is 35-fold, which is very close to the experimental result of 
35.8-fold.  However, the reaction plane model appears to overestimate the ketoprofen 
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flux increase in the bicarbonate buffer, i.e., the model calculates a 16.5-fold, despite of an
experimental value of 10.5-fold. In the case of indomethacin, both the reaction plane 
model and film model appear to underestimate the flux ratio of indomethacin in
phosphates versus in bicarbonates (Table 4.4). Nevertheless, it should be recognized that 
even though neither of the models predicts the experimental results exactly, they both 
reasonably/quantitatively demonstrates the trend of drug flux increase depending on 
buffer concentration and species. The trend is that the dissolution rate of ketorpofen and 
indomethacin is up to 2- fold higher, in the studied phosphates, than that in the
bicarbonates. Thus, both models are suitable for assessment of phosphate and
bicarbonate buffer effects, at least semi-quantitatively.
Dependence of Buffer Differential on Biopharmaceutical Properties of Drugs
Experimentally, this work has showed that ketoprofen and indomethacin
demonstrated up to 200% dissolution rate increase in USP SIF and FaSSIF phosphate
than in the 15 mM bicarbonate buffer. Theoretically, the buffer differential can be 
forecasted reasonably well using reaction plane model and film model. The question is:
for a given new drug entity, what is the magnitude of the buffer differential? To answer 
this question, three key parameters including drug pKa, solubility and diffusion
coefficient, which are used in the theoretical analysis, are investigated to determine their 
importance on the buffer species effects.
The buffer differential effects were indicated by the drug flux ratio in the USP SIF 
to that in the 15 mM bicarbonate.  Theoretical analysis indicated that drug pKa has a 
profound impact on buffer differential, as shown in Figure 4.1.  For weak acids with pKa 
values of 7 or higher, the drug flux ratios in these two tested buffers were close to 1.  This 
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result is reasonable because the ionization difference of these drugs in pH 6.8 USP SIF 
and pH 6.5 bicarbonate is limited.  The observed drug flux is essentially contributed from
the unionized form and thus determined by the intrinsic solubility of the unionized form, 
which should not differ appreciably in various buffers. In comparison, for weakly acidic 
drugs with pKa values of 6.5 or less, their intrinsic dissolution rates is about 50-200%
higher in the USP SIF than that in the 15 mM bicarbonate buffer (Figure 4.1). Thus, the
magnitude of buffer differential depends strongly on drug pKa whose value is in the 
regions of < 6.5, and very weakly in regions of drug pKa > 7.0. It should be noticed that 
this theoretical calculation underestimates the flux ratio in these two tested buffers.  For 
example, the film model and reaction model predicted that the flux ratio of ketoprofen in
these two buffers was 1.77 and 2.12, respectively, which was lower than the experimental 
ratio of 3.33.  A similar result was seen with indomethacin, as shown in Table 4.4, i.e., 
the flux ratio forecasted theoretically was less than the experimental value.
It is also evident from Figure 4.1 that the buffer differential is more sensitive to the 
changes of drug pKa but less to the drug solubility. This high dependence of drug flux
ratio on drug pKa is hypothesized by the following.  It is the drug pKa, rather than the
drug solubility, predominantly controls the extent of ionization of drug molecules at the 
solid- liquid interface. As a result, mainly depending on drug pKa, the amount of ionized 
drug species varies, as reacting with buffer components and thus demonstrating the buffer 
differential.
In addition to drug pKa, drug solubility also plays an important role in considering
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.  Further, the ratio of the relative drug flux in two buffers, i.e., the buffer 
differential, is much weakly dependant on drug solubility, due to a similar magnitude 
change of relative drug flux in two buffers. Tables 4.6-1 and 4.6-2 showed that the buffer 
different ial vary insignificantly with drug solubility variation. In addition to drug pKa 
and solubility, drug diffusivity has a negligible impact on the buffer differential, as 
shown in Tables 4.7-1 and 4.7-2. In summary, the importance of drug properties on the
magnitude of buffer differential decreases in the following order: drug pKa > drug
solubility ˜ drug diffusivity.
Surrogate Buffer Equivalent to the Bicarbonate
As demonstrated evident ly in this work, ketoprofen and indomethacin show higher
intrinsic dissolution rates in the commonly accepted USP SIF and FaSSIF phosphate 
buffer than in the physiological 15 mM bicarbonate buffer. Even though bicarbonate is 
the prevailing human physiological buffer, it is rarely used as an in-vitro dissolution 
media. The decision to not use bicarbonate is mainly due to its inconvenience because 
maintaining a stable bicarbonate buffer system requires an equilibrium between PCO2 (g) 
and the dissolution media at a given pH, which is generally achieved by continuous 
purging CO2 (g) into the media to compensate the fast loss of CO2 to the atmosphere at 
37ºC. Practical considerations lead to the alternative using a simple buffer such as 
phosphate buffer, as a surrogate for the bicarbonate.  The ideal surrogate buffer should
behave similarly to the physiological bicarbonates, exhibit almost the same dissolution 
rates for the same drug, and preferably be easily prepared and maintained. In this work, 
phosphate buffer surrogates for ketoprofen and indomethacin were initially forecasted
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using both the reaction plane model and film model, and then were confirmed using
intrinsic dissolution measurement. For ketoprofen, the reaction plane model and film 
model predicted that 12-14 mM phosphate buffer at pH 6.5 is equivalent to the 15 mM
bicarbonate, and experimentally 13.0 mM phosphate was selected, as shown in Table 4.8.
The intrinsic dissolution rate of ketoprofen in 13.0 mM phosphate buffer is 0.198
mg/cm2/min, which is 85% of 0.231 mg/cm2/min, the dissolution rate in the 15 mM 
bicarbonate.  Similarly, for indomethacin, theoretical analysis predicted that ~3-4 mM
phosphate buffer is suitable as the bicarbonate surrogate.  Then, a 3.5 mM phosphate was 
used, in which the indomethacin intrinsic dissolution rate was 26.0 µg/cm2/min.  This
drug flux is equivalent to 108% of the intrinsic dissolution rate in the bicarbonate.  Here, 
theoretical analysis is useful to recommend a suitable phosphate concentration that is 
replaceable for the bicarbonate. Further, the theoretical approach is supported by the
experimental results. It is also apparent in Table 4.8 that the surrogate phosphate buffer
is not one single universal medium for all drug molecules, but rather it should be 
individualized according to the unique properties of drug molecules including pKa,
solubility and diffusivity. 
Discussion
Significance of Investigating Bicarbonate Buffer
Our work showed that even with FaSSIF, a phosphate buffer with much lower 
concentration of 29 mM at pH 6.5, the dissolution of ketoprofen and indomethacin still
demonstrated higher rate in the FaSSIF than in the bicarbonate. Thus, an in-vitro
dissolution testing in either USP SIF or FaSSIF is generally overestimating the true 
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dissolution rates of ketoprofen and indomethacin in vivo. This overestimation, suggested 
by theoretical analysis, is extrapolated to other BCS II weak acids particularly for those 
with pKa values less than 6.5. Therefore, although the pH value of USP SIF buffer and 
FaSSIF may mimic small intestine fluids, the buffer composition and concentration also
have significant impacts on weakly acidic BCS II drugs.  It is concluded here that not 
only the pH, but also perhaps more importantly, the buffer species and concentrations 
should be considered in composing the in-vitro dissolution media to closely reflect the in
vivo dissolution fluids.
To constitute an ideal in vitro dissolution medium, buffer species and concentration,
pH, bile salts and viscosity of the GI fluids should all be considered. This work was to 
seek the significance of physiological buffer species and concentration, without inclusion 
of any bile salts, in dissolution of BCS II acidic drugs.  The rationale is the following.
Firstly, studying a buffer system without including any other variables such as bile salts 
would distinctively reveal the buffer effects.  Secondly, bile salts at fasting stage may not 
be important, due to its low concentration rage of 3-5 mM, with an average value of 4.3
mM 8. A more recent study reported that the bile salt level in fasted human intestinal 
fluids was 2 ± 0.2 mM 5. Thirdly, even though bile salts contribute significantly on 
solubilization and dissolution of low-solubility drugs, their effects on ionizable drugs 
become minimal if pH change is present.  This is particularly true for drugs with pKa 
values within the pH range of proximal small intestine. Here, the two model compounds 
ketoprofen and indomethacin have pKa values of 4.76 and 4.18, respectively. If the pH
in proximal small intestine is around 6.5, their solubility would be increased
approximately 100-fold.  In comparison, their solubility enhancement from a low
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concentration of 2-5 mM bile salt would be negligible. Our previous studies have 
demonstrated that buffer/pH effects appear to be more important than surfactant effects in 
the case of BCS II acids such as piroxicam 11 and ketoprofen 43.
For neutral drugs such as fenofibrate, the difference between the USP SIF and 
FaSSIF phosphate buffer, from bicarbonates, is significant because no ionization of drug 
molecules would occur at the solid- liquid interface.  The neutral drug would not react 
with the ionic species from the bulk buffer, and the drug dissolution is essentially 
controlled by the intrinsic solubility of the drug.  Thus, buffer species or concentration 
has no impact on the drug dissolution rate.  For BCS II weakly basic drugs, the buffer
differential between the phosphate and bicarbonate should depend on the drug pKa.  For 
a weak base with pKa values close to or higher than the pH range in the small intestine, 
its significant ionization is expected. As a result, the ionized form and the free base form 
react with the buffer components, and the buffer differential effects will be observed. In
comparison, for weak bases with pKa lower than the pH range, and subsequently with 
negligible disassociation, in upper small intestine, a difference between the phosphate 
and bicarbonate is trivial.  Dipyridamole is an example of such drug. Dipyridamole is a 
weak base with pKa value of 6.05 - 6.10, with low solubility of 5.8 µg/mL at 25°C.  At 
pH 6.8, dipyridamole intrinsic flux is independent of the buffer species or concentration, 
where USP SIF, FaSSIF and bicarbonate buffer were employed 27.
Marketed BCS II Weak Acids
Evidently, the magnitude of the buffer effects depends on the biopharmaceutical 
properties of the drug molecule. Table 4.9 lists almost all BCS II weak acidic drugs 
currently on the market in US and foreign countries. All of the listed drugs have pKa 
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values less than 5.5. As demonstrated in this work, significant buffer differetnial between 
USP SIF and FaSSIF, and the bicarbonates, should be expected for any BCS II weak 
acids with a pKa less than 5.5. Specifically, only considering the effect of buffer species, 
the dissolution rates of these weak acids in the USP SIF and FaSSIF are very likely to be
overestimated 50-200% fold of the true values in vivo.
Table 4.9 listed that several BCS II weak acids are marketed as sodium, potassium 
and calcium salts. In general, the salt forms would have a faster dissolution rate than the 
corresponding acid in the upper small intestine. We hypothesized that the salt forms, if 
they belong to BCS II class, should also demonstrate differential dissolution rates in USP 
SIF and FaSSIF relative to the bicarbonate buffers.  This is because at upper small 
intestine the salt form of weak acids generally disassociate to a greater extent than the 
weak acids, and then the ionized acidic component behave similarly to the weak acid
form. Even with very low-solubility salt form such as atorvastatin calcium, which is 
insoluble in aqueous solution at pH equal or below 4.0, and is very slightly soluble in 
distilled water at 37°C 44, the impacts of buffer differential may be similar to the case of 
indomethacin. The extent of buffer differential, however, on the salt forms requires 
further research.
Surrogates for Bicarbonate Buffer
It is evident that the bicarbonates are the best buffer system representing the in vivo
GI situation. Practical considerations, however, lead to the use of easily prepared buffer
systems, such as phosphate buffers to surrogate the bicarbonates. Further, the
concentrations of surrogate phosphate vary significantly depending on the drug pKa and 
solubility.  For drugs with high pKa values such as above pH 7.0, the drug dissolution 
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rate is only weakly influenced by buffer species and concentration. In this scenario, the
commonly used USP SIF or FaSSIF behaves similarly to the bicarbonates. In contrast,
BCS II weak acids with pKa values lower than 5.5, which prevails the current market,
would show a drug flux in USP SIF that is about 50-200% fold of that in the bicarbonates 
(Figure 4.1). To minimize the discrepancy between USP SIF and bicarbonates, a lower 
concentration of phosphate is required to match the drug flux in the bicarbonates at pH 
6.5, as suggested experimentally as well as theoretically in our work. Furthermore, this
work showed that a low-solubility drug may require a lower phosphate buffer to mimic 
the bicarbonates than a relative high-solubility drug with similar pKa.  For example,
ketorpfen with an intrinsic solubility of 9.95×10-4 M requires 13-15 mM of phosphate to 
mimic the bicarbonates, whereas 3-4 mM of phosphate appears to be sufficient for a
lower solubility drug such as indomethacin with solubility of 9.58×10-6 M. The effect of 
drug solubility on the surrogate phosphate concentration may result from the self-
buffering effect of drug molecules at the solid- liquid interface. As the drug molecules 
dissolve and then disassociate into the ionized acid-base pairs, which maintains the 
microenvironmental pH within the boundary layer and functions as self-buffering species 
in contact with the incoming bulk buffers. A weak acid with high solubility has a higher 
concentration of the acid-base pair within the boundary layer, which leads to a higher 
self-buffering capacity and less susceptibility to the changes of bulk buffer.
Dissolution for QC or Bioequivalence
Dissolution tests are used to achieve two major objectives during drug product 
development: 1). to serve as quality control (QC) specification checking the
reproducibility of manufacturing processes and products; and 2). to forecast the in vivo
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performance of drug products. The experimental test conditions for QC are designed to 
detect manufacturing variables and stability changes on storage, whereas test conditions 
for BE should discriminate adequately among products/batches with different in vivo
release behavior. For the QC testing of BCS II weak acids, the USP 13 suggests a wide 
range of dissolution media.  For example, the media used in the USP monograph for 
indomethacin is 20% pH 7.2 phosphate and 80% water, for etodolac (pKa = 4.7) is pH 
6.8 phosphate, and for sulindac (pKa = 4.5) is 0.1 M pH 7.2 phosphate. However, none
of these pharmacopeial monograph phosphate buffers is physiologically relevant. They
are primarily useful in checking reproducibility of products during manufacturing
procedures to meet regulatory requirements, and they poorly predict the in vivo
performance of a drug product.  Therefore, an in vitro bioequivalence (BE) dissolution
testing methodology, with which physiologically relevant conditions in the GI tract can 
be better reflected and the in vivo drug product dissolution can be better estimated, needs 
to be developed.
In addition, as demonstrated experimentally and theoretically in this work, the
dissolution profiles for drugs with pKa < 5.5 are expected to show large differences in the 
monograph phosphate buffer from the physiological bicarbonates. The gap between the 
USP phosphate buffers and physiological bicarbonates may contribute largely to the 
dissolution discrepancy between the in vitro testing and the in vivo situation.
Consequently, when in vivo dissolution is the rate limiting step to absorption of a BCS II 
drug, an expected IVIVC may not be observed. Across the industry, a lack of success has 
been seen in successfully developing an IVIVC for numerous BCS II immediate-release
oral dosage forms. Additionally, if a dissolution medium is designed in order to reach 
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maximum or even 100% of release within the duration of the test, it may satisfy the 
dissolution specification of a product, but generally do not represent the in vivo condition 
and therefore may not be suitable for BE dissolution purposes.  In a typical QC
dissolution testing, more than 75-80% of the drug release has dissolved at the final
evaluation time point.  In contrast, a BE or biorelevant dissolution test for BCS II drugs 
should be aimed to reflect the extent of an in vivo dissolution.
Conclusions
In summary, this work has highlighted the importance of using physiological
buffers when determining the drug intrinsic dissolution rates, particularly for BCS II
weakly acidic drugs. Based on drug pKa, solubility and diffusivity, and buffer
characteristics, theoretical analysis has successfully forecasted the drug flux in various 
phosphates and bicarbonates at least semi-quantitatively. Practical consideration leads to 
the utilization of surrogate buffers such as phosphate to mimic physiological bicarbonates.
It is expected that the bicarbonate surrogate should better reflect the in vivo dissolution 
fluid, thus further improving the in vitro dissolution with the in vivo performance, in
relative to FaSSIF or USP SIF.
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Table 4.1. Commonly used pharmaceutical dissolution media/buffers for simulating
upper small intestine.
Dissolution media pH Buffer components
USP SIF 6.8 Phosphate: 50 mM
1% pancreatin
FaSSIF 6.5 Phosphate buffer: 29 mM
Sodium taurocholate: 3 mM
Lecithin: 0.75 mM
NaOH: adjust pH to 6.5
NaCl: adjust to isotonic
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Table 4.2. Parameters used in theoretical analysis.
Species pKa D (×106), cm2/s M.W. Solubility (M)
Ketoprofen 4.76a 9.3b for HA form
9.2c for A-
254.3 9.95 ×10-4, a
Indomethacin 4.17d 8.0b for HA form
7.9c for A-
253.3 9.58 ×10-6
H2PO4- /HPO42- 7.21e, 6.53f 11.5g 98




a: from the paper submitted to Euro. J. Pharm. Sci.; b: calculated using ADMET Predictor™ based on 
Einstein-Stokes equation for 37°C; c: calculated using harmonic average of HA and H+ forms; d: from D.P. 
McNarmara et al., Pharm. Res., 2003, (20), 1641-1646.; e: at 25°C, from both Physical pharmacy, 4th 
edition, by A. Martin and Lange’s handbook of chemistry, 5th edition, by J.A. Dean, McGraw-Hill, Inc., 
1999.; f: calculated using Gribbs equation (ln Ka=∆G0/RT) with the consideration of temperature.; g:
limiting ionic mobility for H2PO4-, HPO42- and HCO3
-
 at 37°C is 41.6 and 44.5cm2/O/equiv., being
converted to D using the unit conversation factor from D = 2.769 ×10-6λi/Zi (E.L. Cussler, Diffusion); h: at 
25°C, from E.L. Cussler, 2nd ed., 1997, p 112; i: at 37°C, from Lange’s handbook of chemistry, 5th edition, 
by J.A. Dean, McGraw-Hill, Inc., 1999, p 8.168.
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Table 4.3.  Intrinsic flux of ketoprofen in the phosphate and in the bicarbonate buffer 








USP SIF, w/o pancreatin, 
50 mM phosphate buffer
6.8 35.8 35.0 24.1
FaSSIF w/o bile salts, 
29 mM phosphate buffer
6.5 17.6 18.8 12.6
5.0 mM bicarbonate buffer 6.5 6.14 9.67 6.4
15 mM bicarbonate buffer 6.5 10.5 16.5 13.6
20 mM bicarbonate buffer 6.5 14.2 19.4 16.5
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Table 4.4.  Intrinsic flux ratios of indomethacin in the phosphate versus in the 
bicarbonates, experimental and theoretical results.




USP SIF, 50 mM phosphate buffer:
5% CO2, 6.4 mM bicarbonate
6.8 2.42 1.68 1.69
USP SIF, 50 mM phosphate buffer:
10% CO2, 12.9 mM bicarbonate
6.8 1.67 1.34 1.28
USP SIF, 50 mM phosphate buffer:
15% CO2, 19.3 mM bicarbonate
6.8 1.53 1.21 1.17
USP SIF, 50 mM phosphate buffer:
20% CO2, 25.8 mM bicarbonate
6.8 1.39 1.14 1.09
USP SIF, 50 mM phosphate buffer:
15 mM bicarbonate
6.8:6.5 2.80 1.92 1.89
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Table 4.5.  Intrinsic dissolution rates of ketoprofen in 50mM pH 6.8 phosphate and 
bicarbonate buffers.
Buffer components pH Mean flux (mg/cm2/min)
(n = 3, S.D.)
Experimental
(Ntotal/N0)
USP SIF, 50 mM
phosphate buffer
6.8 0.783 (0.010) 35.8
50 mM bicarbonate 
buffer
6.8 0.352 (0.003) 16.1
SGF, 0.1 N HCl 1.2 0.022 (0.001) 1.0
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Table 4.6-1.  Drug flux ratio in USP 50 mM phosphate and 15mM bicarbonate buffers:
the impact of drug solubility and drug diffusion coefficient (drug pKa = 3).
Drug diffusion coefficient (×10-5 cm2/s)
Drug Solubility (M) 0.1 0.5 1.0 5.0
1×10-8 2.0 2.0 1.99 1.98
1×10-7 1.99 1.99 1.95 1.92
1×10-6 1.98 1.90 1.85 1.79
1×10-5 1.85 1.79 1.81 1.90
1×10-4 1.81 1.94 1.99 2.03
1×10-3 1.99 2.02 1.99 1.81
Table 4.6-2.  Drug flux ratio in USP 50 mM phosphate and 15 mM bicarbonate buffers:
the impact of drug solubility and drug diffusion coefficient (drug pKa = 5).
Drug Solubility (M) Drug diffusion coefficient (×10-5 cm2/s)
0.1 0.5 1.0 5.0
1×10-8 1.97 1.97 1.97 1.97
1×10-7 1.97 1.99 1.97 1.97
1×10-6 1.97 1.97 1.96 1.95
1×10-5 1.96 1.96 1.93 1.88
1×10-4 1.95 1.87 1.82 1.75
1×10-3 1.82 1.74 1.74 1.73
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Table 4.7-1.  Drug flux ratio in USP 50 mM phosphate and 15 mM bicarbonate buffers: 
the impact of drug pKa and drug diffusion coefficient (drug solubility = 1×10-8 M).
Drug diffusion coefficient (cm2/s)
Drug pKa 1×10-6 5×10-6 1×10-5 5×10-5
3.0 2.0 2.0 1.99 1.98
3.5 2.0 2.0 2.0 1.99
4.0 2.0 2.0 1.99 2.0
4.5 1.99 1.99 1.99 1.99
5.0 1.97 1.97 1.97 1.97
5.5 1.91 1.91 1.91 1.91
6.0 1.76 1.76 1.76 1.76
6.5 1.50 1.50 1.50 1.50
7.0 1.24 1.24 1.24 1.24
8.0 1.03 1.03 1.03 1.03
Table 4.7-2.  Drug flux ratio in USP 50mM phosphate and 15 mM bicarbonate buffers:
the impact of drug pKa and drug diffusion coefficient (drug solubility = 1×10-3 M).
Drug diffusion coefficient (cm2/s)
Drug pKa 1×10-6 5×10-6 1×10-5 5×10-5
3.0 1.99 2.02 1.99 1.81
3.5 1.89 1.99 2.00 1.88
4.0 1.80 1.92 1.94 1.88
4.5 1.78 1.80 1.84 1.82
5.0 1.82 1.74 1.74 1.73
5.5 1.84 1.72 1.68 1.61
6.0 1.74 1.66 1.61 1.50
6.5 1.50 1.47 1.44 1.37
7.0 1.24 1.23 1.23 1.20
8.0 1.03 1.03 1.03 1.03
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Table 4.8. Phosphate buffer as an equivalent substitute for 15 mM bicarbonate buffer.
Buffer components (pH 6.5) Ketoprofen Indomethacin
Exp. Drug flux (S.D) 
(mg/cm2 /min)
Exp. Drug flux (S.D.) 
(µg/cm2/min)
29 mM phosphate 0.386 (0.010) 40.0 (3.5)
15 mM bicarbonate 0.231 (0.002) 24.0 (4.8)
Theoretical analysis Theoretical phosphate concentration (mM)
Reaction plane model 12.0 < 3.0
Film model 13.7 ~ 4.0
Exp. phosphate 13.0 3.5
Exp. drug flux (S.D.) using 
the bicarbonate substitute
0.198 (0.004) 26.0 (0.3)
Proficiency to bicarbonate 86% 108%
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3.5 45 975 Free acid BCS I or III
Atorvastatin 4.46 45 80 Calcium salt BCS II 46
Diacerein 4.74* 50 Free acid non-us marketed drug
Diclofenac 4.2 47 50 K and Na salts BCS II
Diflunisal 3.0 45 500 Free acid BCS II
Etodolac 4.7 45 400 Free acid BCS II
Epalrestat 3.2* 50 Free acid non-us drug
Fenoprofen 4.5 47 600 Calcium salt BCS II
Flurbiprofen 4.3 47 100 Free acid BCS II
Fluvastatin 4.76* 40 Na salt BCS II
Furosemide 3.88,
9.37* 80 Free acid
BCS II
Ibuprofen 4.4 47 800 Free acid BCS II
Indomethacin 4.5 47 50 Free acid BCS II





Salt form: BCS I
Mefenamic
acid 4.2 45 250 Free acid
BCS II







Acid: BCS II 49
Na salt: BCS I 50
Oxaprozin 4.3 48 600 Free acid BCS II
Piroxicam 1.8, 5.1 48 20 Free acid BCS II
Salicylic acid 3.0 45 750 Free acid BCS I
Sulindac 4.5 47 200 Free acid BCS II
Triflusal 4.15* 300 Free acid non-us drug
Tolmetin 51 3.5 47 600 Na salt BCS II
Zaltoprofen 4.44* 80  Free acid non-us drug
Warfarin 5.35* 10 Na salt 52 BCS I
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CHAPTER V 
SUMMARY
So far, dissolution testing is one of the most widely employed quality control 
criteria for oral drug products.  Using the current dissolution methods as a predictive tool
for the in vivo performance of a drug product, however, is very difficult if not impossible.
has been frequently encountered in pharmaceutical product development, with 
pharmacopeia dissolution testing often either over- or under- discriminating the in vivo
dissolution behavior for an immediate drug product.  Evidently, the gap between in vitro
dissolution results and in vivo dissolution are largely caused by the discrepancy between 
in vitro dissolution design and in vivo GI environment.   project was thus to focus on 
mechanistically investigating key in vitro dissolution parameters that can closely reflect 
in vivo drug dissolution, with the ultimate goal to design a bioequivalent dissolution
methodology.
To achieve this goal we started investigating the effect of particle size and paddle 
speeds on the diffusional layer thickness in a USP dissolution apparatus II. 
Fenofibrate, a neutral and poorly soluble drug with a single polymorph, was selected as 
the model compound.  In the literature, the dependence of on particle size assumes
various relationships.  Popular among them includes 
apph
apph
apph r  or as a constant based




rotating bottle.  One immediate goal of this work is to examine how is related to
particle radius r in a pharmaceutically relevant system such as a USP dissolution vessel. 
It is surprising that even with global usage of the USP paddle device, this relationship has 
not been experimentally determined through powder dissolution testing.  It is well known 
that is a function of fluid velocity.  Unfortunately, the dependence of  on paddle
speeds or fluid velocity has been largely ignored in pharmaceutical field.  This work 
demonstrated that the dependence of h
apph
apph apph
app on particle size follows different functions in 
accordance with the paddle speed.  At 50 rpm, the function of happ is best described by a 
linear plot of 9.91 23.31apph d  ( ) throughout the particle size range of 6.8-
106 m.  In contrast, at 100 rpm a transitional particle radius of 23.7 m exists, under 
which a linear relationship of 
2 0.98R
1.59apph r  ( ) manifests, but above which h
2 0.98R app
becomes a constant of 43.5 m.  Further, the effect of particle size and paddle speed on 
happ was combined using dimensionless analysis.  Within certain fluid velocity/particle
size regime, linear correlation of app
h
d
with the square-root of Reynolds number 1/ 2( )d ,
i.e., 4 1/ 21.5207 9.25 10 ( )app
h d
d
2 0.9875R ( ), was observed.  One unique finding 
of  work is the independence of diffusional layer thickness on fluid velocity for the drug 
particles in micron range.   certainly merits further investigation considering the current 
technological trend of micronizing and nanonizing.  In addition, the application of 
apparent diffusion layer thickness to the real drug powder namely polydispersed 
powder, should be investigated in the future.  Further, in this work a non-ionized 




speed for ionizable BCS II drugs such as weak acids and bases is yet to be conducted. 
Conceivably, in addition to diffusion and convection, the reaction term can be included 
into the apparent .apph
The other objective of this work is to design in vitro dissolution media closely 
reflecting in vivo GI fluids.  To accomplish  goal, two research investigations were 
conducted: 1). The combined effects of pH and surfactants in solubilization and 
dissolution of a BCS II acid ketoprofen; 2). The buffer differential between bicarbonate 
and phosphate in dissolution of ketoprofen and indomethacin. A lot of attention has been 
paid to the pH of dissolution media so that they match the pH changes along GI tract. 
Surfactants as economic substitute for bile salts have been examined by several
investigators recently.  When the effects of pH and surfactants were combined and 
compared,  work revealed that pH is the far more important factor than surfactants (bile
salts) in solubilization and dissolution of a BCS II weak acid with a pKa value within the 
GI pH range, mainly because pH has the log-scale effect whereas surfactant has a linear 
effect on ionizable drug dissolution.  Surfactants are still important in constituting 
dissolution media especially for non-ionizable low-solubility drugs.  Further, even at the 
same pH and with the same buffer concentration, BCS II weak acids still exhibit different 
dissolution rates depending on the buffer species.  Therefore, bicarbonate as a key buffer 
species in dissolution medium was investigated.   work demonstrated the buffer
differential between bicarbonates and phosphates both experimentally using rotating disk 
method and theoretically using reaction plane model and film model.  Specifically, the 
intrinsic dissolution rates of ketoprofen and indomethacin in USP and FaSSIF phosphate 
buffers are 50-200% faster than those in 15 mM bicarbonates, which is in good 
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agreement with the theoretical trendline.  Using theoretical approach, the buffer
differential was demonstrated to depend on the biopharmaceutical properties of API in 
the following decreasing order: drug pKa > drug solubility  drug diffusivity.  The
significance of this finding is that for a given new drug candidate, the effects of buffer 
species can be forecasted and then appropriate buffer can be selected in dissolution
testing.  Even though bicarbonate is in vivo buffer system, its utilization in practice is 
inconvenient due to difficulty of maintaining CO2 concentration in aqueous phase. 
Therefore, through theoretical prediction and experimental results a simple buffer such as 
phosphate buffer can be recommended, in which the dissolution rates of an API is
equivalent to that in the bicarbonates.  Specifically, in this work I showed that at pH 6.5 
ketoprofen and indomethacin require 13 -14 mM and 3-4 mM phosphate buffer to match
85% and 108% of the dissolution rates in 15 mM bicarbonate buffer, respectively.  Both 
phosphate concentrations are far below than the USP SIF and FaSSIF, suggesting that the 
current phosphates are very likely overestimate the true dissolution rates in vivo.  Much
work remains in designing the optimal dissolution media to mimic in vivo fluids.   is 
because in vivo fluids inevitably change along the GI tract and vary among individuals. 
Therefore, one single dissolution medium can not possibly reflect the complexity and 
dynamic of GI fluids.  I trust that this work will at least lead the colleagues’ attention to 
and stimulate interest in bicarbonates or its surrogates when constituting a BE dissolution
medium.
In the future, in order to establish a meaningful bioequivalent methodology,
hydrodynamics, choice of dissolution media, and interplay between these two should be 
all carefully considered.
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